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ABSTRACT  
 
Positron emission tomography (PET) is a molecular imaging technique that utilises 
radiopharmaceuticals (radiotracers) labelled with a positron-emitting radionuclide, such as 
fluorine-18 (18F).  Development  of  a  new  radiotracer  requires  an  appropriate  radiosynthesis  
method:  the  most  common of  which  with  18F is nucleophilic substitution with [18F]fluoride 
ion ([18F]F-). The success of the labelling reaction is dependent on various factors such as the 
reactivity of [18F]F-, the structure of the target compound in addition to the chosen solvent. 
The overall radiosynthesis procedure must be optimised in terms of radiochemical yield and 
quality of the final product. Therefore, both quantitative and qualitative radioanalytical 
methods are essential in developing radiosynthesis methods. Furthermore, biological 
properties of the tracer candidate need to be evaluated by various pre-clinical studies in 
animal models. 
In this work, the feasibility of various nucleophilic 18F-fluorination strategies were studied 
and a labelling method for a novel radiotracer, N-?3-[18F]fluoropropyl)-2?-carbomethoxy-3?-
?4-fluorophenyl)nortropane (?18F??-CFT-FP),  was  optimised.  The  effect  of  solvent  was  
studied by labelling a series of model compounds, 4-(R1-methyl)benzyl R2-benzoates. 18F-
Fluorination reactions were carried out both in polar aprotic and protic solvents (tertiary 
alcohols). Assessment of the 18F-fluorinated products was studied by mass spectrometry (MS) 
in addition to conventional radiochromatographic methods, using radiosynthesis of 4-
[18F]fluoro-N-[2-[1-(2-methoxyphenyl)-1-piperazinyl]ethyl-N-2-pyridinyl-benzamide (p-
[18F]MPPF) as a model reaction. Labelling of ?18F??-CFT-FP was studied using two 18F-
fluoroalkylation reagents, ?18F?fluoropropyl bromide and ?18F?fluoropropyl tosylate, as well 
as by direct 18F-fluorination of sulfonate ester precursor. Subsequently, the suitability of 
?18F??-CFT-FP for imaging dopamine transporter (DAT) was evaluated by determining its 
biodistribution in rats. 
The results showed that protic solvents can be useful co-solvents in aliphatic 18F-
fluorinations, especially in the labelling of sulfonate esters. Aromatic 18F-fluorination was not 
promoted in tert-alcohols. Sensitivity of the ion trap MS was sufficient for the qualitative 
analysis of the 18F-labelled products; p-[18F]MPPF was identified from the isolated product 
fraction with a mass-to-charge (m/z) ratio of 435 (i.e. protonated molecule [M+H]+). ?18F??-
CFT-FP was produced most efficiently via ?18F?fluoropropyl tosylate, leading to sufficient 
radiochemical yield and specific radioactivity for PET studies. The ex vivo studies in rats 
showed fast kinetics as well as the specific uptake of ?18F??-CFT-FP to the DAT rich brain 
regions. Thus, it was concluded that [18F]?-CFT-FP has potential as a radiotracer for imaging 
DAT by PET.  
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DMSO   dimethylsulfoxide 
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EtOAc    ethylacetate 
ex vivo  study of biological process in a living organism, samples are taken after 
death  
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p-[18F]MPPF 4-[18F]fluoro-N-[2-[1-(2-methoxyphenyl)-1-piperazinyl]ethyl-N-2-
pyridinyl-benzamide 
HEX   hexane 
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HPLC   high performance liquid chromatography 
GBR12909 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine 
ICY    incorporation yield 
ID  injected dose 
in situ  production of chemical intermediates in the reaction mixture 
in vitro  study of biological process in artificial conditions using e.g. tissue slides 
in vivo  study of biological process in a living organism  
i.v.  intravenous(ly) 
K 2.2.2    Kryptofix 2.2.2 = 4,7,13,16,21,24-hexaoxa-1,10-
diazabicyclo[8.8.8]hexacosane 
logP logarithm of partition coefficient between octanol and water; termed logD 
when measured at physiological pH, 7.4  
p-MPPF  4-fluoro-N-[2-[1-(methoxyphenyl)-1-piperazinyl]ethyl-N-2-pyridinyl-
benzamide  
p-MPPNO2 4-nitro-N-[2-[1-(methoxyphenyl)-1-piperazinyl]ethyl-N-2-pyridinyl-
benzamide 
NCA    no-carrier-added 
NET   noradrenaline transporter 
NMR   nuclear magnetic resonance 
nor-?-CFT 2?-carbomethoxy-3?-(4-fluorophenyl)nortropane 
OMs    methanesulfonyl ester, mesylate 
OTf    trifluoromethanesulfonyl ester, triflate 
OTs    toluenesulfonyl ester, tosylate 
PET   positron emission tomography 
PSL  photo-stimulated luminescence 
p.i.  post-injection 
RCY   radiochemical yield 
Rf   retardation factor 
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RT   room temperature 
SA  specific (radio)activity 
SERT   serotonin transporter 
SPE   solid phase extraction 
SN2    bimolecular nucleophilic substitution 
SNAr   aromatic nucleophilic substitution 
T1/2   physical half-life of radionuclides 
t-amyl alcohol tertiary amyl alcohol,  2-methylbutan-2-ol  
TBAOH  tetrabutylammonium hydroxide 
t-BuOH   tertiary butanol, 2-methylpropan-2-ol 
TEA   triethylamine 
THF    tetrahydrofurane 
TLC    thin-layer chromatography 
TMS   tetramethylsilane 
Tos-?-CFT-FP  N-(3-tolylsulfonyloxypropyl)-2?-carbomethoxy-3?-(4-fluorophenyl)nor-
tropane 
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1. INTRODUCTION  
 
Fluorine-18 (18F) is the most widely used radionuclide in radiopharmaceuticals (radiotracers) 
for imaging with positron emission tomography (PET). The majority of the 18F-labelled 
radiotracers are produced by nucleophilic 18F-fluorination, either by direct substitution with 
[18F]fluoride ion ([18F]F-) or by a multistep approach using 18F-fluorinated prosthetic groups. 
Success of the substitution reaction, determined by a high radiochemical yield of the desired 
18F-labelled product, is dependent on various factors such as the reactivity of the [18F]F-, the 
structure of the target compound, as well as the solvent. The state-of-the-art method for 
nucleophilic 18F-fluorination involves the production of a dry Kryptofix 2.2.2/[18F]KF 
complex and subsequent labelling reaction in polar aprotic solvent such as acetonitile 
(CH3CN), dimethylformamide (DMF) or dimethylsulfoxide (DMSO). Recent studies utilising 
tertiary alcohols as solvents have demonstrated a novel approach to enhance nucleophilic 
fluorinations; however, more information is needed regarding the suitability of protic solvents 
in labelling with [18F]F-, that is in tracer conditions.  
18F-Labelled radiotracers are valuable in the monitoring of neurological function in the brain 
by PET. Several labelled compounds have been developed for the visualisation of dopamine 
transporter (DAT), which is an important target for a variety of clinically effective 
therapeutic drugs, neurotoxic agents and stimulant drugs of abuse, like cocaine. Moreover, 
DAT binding sites are affected in several neurodegenerative and psychiatric disorders such as 
Parkinson’s disease. Radiotracers for DAT are typically cocaine derivatives in which the 
tropane structure is modified to yield a potentially better ligand for DAT. However, poor 
selectivity and/or unfavourable kinetics of most of the compounds have limited their use in 
quantitative PET and a tracer with improved pharmacokinetic properties is still needed. 
In this work, three 18F-labelled compounds were synthesised in order to study the feasibility 
of various nucleophilic 18F-fluorination  strategies.  First,  the  effect  of  protic  solvent  was  
studied by labelling a series of model compounds, 4-(R1-methyl)benzyl R2-benzoates. 
Second, a serotonin receptor 5-HT1A ligand 4-[18F]fluoro-N-[2-[1-(2-methoxyphenyl)-1-
piperazinyl]ethyl-N-2-pyridinyl-benzamide (p-[18F]MPPF) was labelled using microwave 
heating in addition to conventional thermal heating: mass spectrometry (MS) was used for the 
characterisation of the radioactive by-products. Third, direct 18F-fluorination as well as two 
18F-fluoroalkylation methods were compared in order to find the optimal radiosynthesis 
method for a novel radiotracer for DAT, N-?3-[18F]fluoropropyl)-2?-carbomethoxy-3?-?4-
fluorophenyl)nortropane (?18F??-CFT-FP): in tandem, a Carbon-11 (11C) alkylation labelling 
method was also studied. Finally, suitability of ?18F??-CFT-FP  for  imaging  DAT  was  
evaluated by determining its biodistribution ex vivo in rats. 
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2. REVIEW OF THE LITERATURE 
 
2.1. Positron emission tomography (PET) 
2.1.1. Principle of PET 
Positron emission tomography (PET) is a molecular imaging technique that utilises 
radiopharmaceuticals labelled with a positron emitting radionuclide. Radiopharmaceuticals 
are introduced into the investigated subject, human or experimental animal, where they are 
distributed by their biological properties and subsequently detected externally. The imaging 
method is based on the simultaneous detection of two 511 keV gamma rays that are emitted 
in opposite directions from a positron decaying radionuclide after interaction with matter, that 
is, the positron is annihilated by colliding with an electron (Fig. 1). The positron range in the 
tissue is dependent on the energy of the radionuclide: thus, the lower the energy (i.e. the 
shorter path before in vivo annihilation), the higher spatial resolution images can be achieved. 
A  PET  scanner  consists  of  a  series  of  scintillation  detectors,  placed  in  a  ring  around  the  
subject, that are measuring the coincidence signals from various planes simultaneously and 
the data is reconstructed in a 3D-image (Brownell and Sweet 1953, Kuhl and Edwards 1968, 
Phelps et al. 1975, Humm et al. 2003, Zanzonico 2004). By the PET technique, concentration 
of the labelled compound can be measured quantitatively (Logan 2003, Laruelle et al. 2002), 
it also offers greater sensitivity and higher resolution compared to another important 
biomedical imaging method, single photon emission computed tomography (SPECT) 
(Vallabhajosula 2009, O’Connor and Kemp 2006). 
 
 
Fig. 1. Schematic representation of the principle of PET  
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2.1.2. Positron emitting radionuclides 
Positron emitters are neutron deficient radionuclides that decay to a stable state by emitting a 
positron, i.e. by  ?+-decay. These radionuclides have an excess amount of positive charge in 
the atom nucleus that is released by a reaction in which one proton is converted to a neutron, 
and a positron (and a neutrino) is emitted. Alternatively, the extra charge can be neutralised 
by taking orbital electrons from the inner shells of the atom, thus by electron capture (EC). 
Properties of the four most common positron emitters used in PET, namely Oxygen-15 (15O), 
Nitrogen-13 (13N), 11C and 18F,  are  presented  in  Table  1.  These  PET-radionuclides  are  
relatively short-lived and easily accessed by nuclear reactions in cyclotrons in which an 
appropriate target, gas or liquid, is bombarded with accelerated protons or deuterons. Some 
longer-lived radionuclides with potential applications in PET, Copper-64 (64Cu) and Iodine-
124 (124I) (physical half-lives (T1/2) 12.7 h and 100.8 h, respectively), as well as the Bromine-
76 (76Br,  T1/2 = 16.1 h), are also produced in medical cyclotrons (Schlyer 2003), whereas 
some important positron emitters, such as Gallium-68 (68Ga,  T1/2 =  68  min),  are  available  
from radionuclide generators (Welch and McCarthy 2000). 
 
Table 1. Physical properties and production reactions for commonly used PET radionuclides 
Nuclide T1/2 
 
[min] 
Decay 
mode 
Maximum 
energy 
[MeV] 
Maximum 
range1 
[mm] 
Main production 
reaction 
Maximum 
theoretical SA  
[GBq/µmol] 
15O 2.04 ?+, 100% 1.73 8.2 14N?d,n)15O 3.39×106 
13N 9.97 ?+, 100% 1.20 5.4 16O?p,?)13N 6.99×105 
11C 20.4 ?+, 100% 0.96 4.1 14N?p,?)11C 3.41×105 
18F 109.8 ?+, 97%;  0.63 2.4 18O(p,n)18F; 6.32×104 
  EC, 3%   as F-/F2  
     20Ne(d,?)18F; as F2  
1 Maximum range in water. 
SA = specific radioactivity, EC = electron capture 
 
2.1.3. PET applications 
PET can be used to image various molecular events in vivo, providing that a suitable 
radiolabelled molecule, such as a peptide, receptor ligand or enzyme target, exists. As these 
radiopharmaceuticals are designed to trace the in vivo behaviour  of  a  natural  substance  or  
certain biological process, the terms radiotracer or radioligand, describing specific receptor 
interactions, are also used. The use of short-lived radionuclides and PET gives a sufficiently 
low radiation dose to the subject; furthermore, repeated investigations can be performed 
within short time intervals. PET has a range of clinical applications, including in cancer 
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diagnosis and the characterisation of various neurological disorders and coronary heart 
disease (Wood et al. 2007, Herholz and Heiss 2004, Neglia et al. 2008). It can also serve as a 
tool for evaluation of new drug candidates and determination of drug effectiveness or optimal 
dose (Paans and Vaalburg 2000, Halldin et al. 2001, Talbot and Laruelle 2002, Bergström et 
al. 2003, Quilloteau and Chalon 2005). In the last decade, the appearance of combined 
techniques, such as PET combined with computed tomography (CT) or more recently with 
magnetic resonance imaging (MRI), has increased the possibilities and use of PET in clinical 
nuclear medicine, especially in the field of oncology (Schöder et al. 2003, Kim E.E. 2008, 
Pichler et al. 2008, Huang 2011).  
 
 
2.2. Radiopharmaceuticals for PET  
2.2.1 Design of a new radiotracer for brain imaging  
An optimal PET-radiotracer for brain imaging has following general characteristics: rapid 
plasma clearance and subsequent high and specific uptake to its target, low nonspecific 
binding and preferably low peripheral metabolism (Vallabhajosula 2009). Detection of the 
signal with a high contrast requires sufficiently high accumulation to the target as well as low 
background. Furthermore, rapid clearance from nonspecific areas is necessary to determine 
specific uptake (Elsinga 2002). Thus, the following parameters should be considered in the 
design of a new radiotracer: 
Lipophilicity of the tracer (logP or logD) determines the ability of the molecule to cross cell 
membranes and other biological barriers. A certain degree is required for the penetration of 
the blood brain barrier (BBB); however, too high lipophilicity (logP > 3) may result in 
increased nonspecific binding due to hydrophobic interactions with lipids and proteins. A 
typical logP value for brain radiotracers is between 1.5 and 3 (Miller et al. 2008). 
Accumulation in the desired target depends on the affinity of the tracer (Kd or Ki, typically at 
nanomolar level), as well as the number of available binding sites (Bmax). The downside of a 
very high affinity (Kd < 0.1 nM) is that it may lead to undesirable, slow and irreversible, 
binding kinetics (Laakso et al. 1998). For kinetic modelling, it is preferred that binding 
equilibrium is reached during the course of the PET experiment. Irreversible tracer types are 
also less sensitive to the transport rate by blood flow, which is often affected in pathological 
conditions  or  by  anaesthesia  (Laruelle  et  al.  2002,  Laakso  and  Hietala  2000,  Halldin  et  al.  
2001). Selectivity is of great importance if the target region has specific competing binding 
sites. For example, a DAT ligand with poor selectivity may also bind to other monoamine 
transporters due to their close structural relationships (Fowler et al. 1989). Stereochemistry 
of the compounds can affect both the active transport mechanisms and binding affinity to 
certain receptors (Halldin et al. 1995, Elsinga 2002). Specific radioactivity (SA), determined 
as the radioactivity per unit mass of the labelled compound (typically expressed in moles), is 
an especially important parameter for receptor ligands and toxic compounds. Receptors are 
typically present in rather low abundance. Furthermore, to avoid any pharmacological effect, 
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especially in small animal studies, radioligands should be used in a low mass dose, no greater 
than microgram level. A typical SA required for PET-tracers is in the order of 50-500 
GBq/µmol (Miller et al. 2008). Finally, the radioactive label should be in a metabolically 
stable  position,  or  alternatively  give  rise  to  hydrophilic  radiometabolites that are unable to 
cross the BBB and cannot thus disturb the signal of the original tracer (Halldin et al. 2001).  
 
2.2.2. General radiosynthesis strategies 
When working with short-lived radionuclides, the production of sufficient amounts of 
radiotracers with adequate SA, creates certain chemistry related challenges: The overall 
synthetic procedures, including the purification and formulation of the desired labelled 
product, need to be fast (? 3 half-lives). Thus, it is desirable to introduce the label to the 
molecule of interest at the latest possible stage. Radionuclides are present in nanomolar 
amounts, enabling faster and more efficient reactions when compared with traditional organic 
chemistry,  but  at  the  same  time  even  a  small  amount  of  impurity  can  disturb  the  labelling  
reaction. Demand for high SA presumes synthesis procedures without the addition of a 
carrier, thus radioactivity losses can also have a dramatic effect on the radiochemical yield. 
Furthermore, as working with high-energy gamma-sources and high radioactivity levels, all 
manipulations should be done in lead-shielded hot cells and preferably using automated or 
remote-controlled systems (Miller et al. 2008).  
In addition to 18F, 11C is an important radionuclide in developing radiotracers for clinical 
applications. The major advantage of 11C over 18F is that the stable carbon in natural 
compounds is easily substituted with 11C without changing the pharmacological properties of 
the molecule. Furthermore, due to the relatively short T1/2, 20.4 min, multiple imaging studies 
can be performed in the same subject within a short period of time. However, the labelling 
chemistry is restricted to the few readily available 11C-labelling precursors that are produced 
in the target, 11CO2 and 11CH4, or subsequently converted into secondary 11C-labelling 
precursors (Christman et al. 1975, Långström and Lundqvist 1976, Långström et al. 1999, 
Ferrieri 2003). The majority of the labelling reactions are simple 11C-methylations on 
nucleophilic C, N, O and S atoms using, for example, [11C]methyl iodide (Bolton 2001, 
Miller et al. 2008). Furthermore, conversion to [11C]methyl triflate has afforded a more 
efficient labelling reagent (Jewett 1992, Någren et al. 1995a, b, Lundkvist et al. 1998). The 
theoretical specific radioactivity of 11C is a magnitude higher than 18F (Table 1.). However, in 
practice the ubiquitous sources of stable carbon (contamination of the target and gas lines) 
decreases the SA of the primary 11C-precursors to 370-3700 GBq/µmol (higher values are 
obtained with 11CH4 than 11CO2) (Vallabhajosula et al. 2009), thus to a level similar to that 
measured for [18F]F- production.  
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2.2.3. Purification and analysis of radiopharmaceuticals 
Radiopharmaceuticals have several important quality criteria such as radionuclidic and 
radiochemical identity, as well as radionuclidic, radiochemical and chemical purity. High SA 
is of great importance especially in in vitro studies; intravenously (i.v.) administered 
compounds (to animals or humans) need to fulfill more extensive quality criteria, including 
sterility and non-pyrogenicity. Radiopharmaceuticals for human use are therefore produced in 
accordance with good manufacturing practices (GMP) (Saha 1997, EU Guidelines to GMP). 
Moreover, specific guidelines for quality assurance and control, taking into account the 
labelling method, have been defined for many PET-tracers (European Pharmacopoeia; 
European Association of Nuclear Medicine (EANM) current good radiopharmacy practices).  
Syntheses of 18F-and 11C-tracers typically involve one or more purification steps to separate 
the desired labelled product from radiochemical impurities, nonlabelled starting material and 
other reagents (and solvents) present in excess amounts. Semi-preparative high performance 
liquid chromatography (HPLC) combined with radioactivity detection is a widely used 
method in the final purification of PET tracers. In addition, various solid-phase extraction 
(SPE) methods, mainly as compact commercial cartridges made of materials such as 
octadecyl bonded silica gel (C-18) or ion exchange resins, are nowadays utilised both at the 
end of synthesis, for purification and formulation of the final product (Lemaire et al. 1999, 
Mitterhauser et al. 2003, Zheng and Mock 2005, Riss and Roesch 2009), as well as in the 
separation of intermediate, mainly 18F-labelled products (Lundkvist et al. 1997, Goodman et 
al. 2000).  
Radiochemical quality control of the short-lived radiotracers is typically realised using fast 
and efficient liquid chromatographic techniques that have high sensitivity and chemical 
resolution, such as radio-HPLC and nowadays also ultra performance LC (Franck et al. 
2009). Alternatively, thin-layer chromatography (TLC) can be used. Combined to improved 
radioactivity detection techniques, radioactivity scanning (Solin 1983) and above all digital 
photo-stimulated luminesence (PSL) autoradiography (Okuyama et al. 1994), it has offered 
faster and higher resolution methods when compared to traditional film autoradiography 
(Kämäräinen et al. 2006). Radio-TLC and especially automated high-performance-TLC 
(HPTLC) methods are suitable for the analysis of small samples, thus they are used 
extensively in the determination of radiometabolites from biological samples (Haaparanta et 
al. 2006). In addition to the simple and fast radiochromatographic methods required for 
routine quality control, more complex analytical methods can be utilised in the development 
of radiopharmaceuticals. For example, MS coupled to a LC method has become an important 
tool for qualitative analyses of the labelled compounds: it has been utilised in the 
determination of specific radioactivity (Hyllbrant et al. 1999, Ma et al. 2003) and in the 
identification of radiometabolites (Lavén et al. 2006).  
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2.2.4. Pre-clinical methods of radiopharmaceutical development  
Once a potential new PET-tracer and a suitable labelling method have been developed, 
biochemical and pharmaceutical properties of the candidate must be evaluated using various 
in vitro, ex vivo and in vivo methods. Binding potency to a certain target, the specificity and 
affinity of the radiotracer, can be evaluated preliminarily by in vitro techniques using post 
mortem human brain slices for example (Young et al. 1986). Digital autoradiography on 
whole brain slices and regions of interest give information on the binding of the tracer 
(Sihver et al. 1999); selectivity can be estimated using specific nonlabelled (drug) inhibitors, 
such as piperazine derivative 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-
phenylpropyl)piperazine (GBR12909) for the dopamine transporter (Heikkilä and Manzino 
1984, Andersen 1989, Lundkvist et al. 1995). To study pharmacokinetic properties of the 
radiotracer, ex vivo and in vivo methods are needed. In ex vivo studies the labelled compound 
is injected into the living animal and thereafter its biodistribution is determined as a function 
of time (by measuring radioactivity of various post mortem organ/tissue samples). 
Calculation of target-to-non-target ratios gives information on the specificity; pre-treatment 
with specific inhibitors both to the desired target and possible competing sites helps to 
evaluate selectivity (Lundkvist et al. 1997). Eventually, suitability of the tracer candidate for 
PET studies is evaluated by in vivo imaging of rodents and/or non-human primates; blood 
samples are collected continuously during the study and analysed for radiometabolites to 
determine the radiometabolic rate (Ametamey and Honer 2007, Haaparanta et al. 2004).  
In the field of neuroscience, rats have traditionally been favoured over mice as an 
experimental animal, mainly due to the bigger size, making them easier for surgical 
manipulation, in addition to the extensive knowledge of both the anatomy and function of the 
rat brain. However, today the high spatial resolution PET scanners designed for small animal 
studies (Weber and Bauer 2004, Cherry 2006) have enabled the use of mice, particularly 
transgenic variants, which has opened new possibilities in imaging gene expression 
(Herschman 2003, Peñuelas et al. 2004). The significant advantage of small animal PET is 
that human diseases can be studied in animal models, such as the monitoring of striatal 
dopaminergic function in rat models of Parkinson’s disease (Hume et al. 1996, Brownell et 
al. 1998, Jacobs et al. 2003), thus accelerating the transition from pre-clinical to clinical 
studies. Moreover, lesioned or genetically altered animals can be studied non-invasively over 
time, which reduces the number of animals employed. Major steps in the development of a 
new radiotracer for PET are depicted in Fig. 2. 
17 
 
 
 
Fig. 2. Major steps in the development of a new radiotracer 
 
2.2.5. Radiotracers for the dopamine transporter 
DAT is a member of a large family of high-affinity, Na+/Cl--dependent neurotransmitter 
transporters (Nelson 1998). DAT plays a significant role in the inactivation and recycling of 
dopamine (DA), one of the most important neurotransmitters in the central nervous system. 
DAT-mediated reuptake of released DA is generally thought to be the primary mechanism for 
controlling the spatial and temporal aspects of DA neurotransmission (Hoffman et al. 1998, 
Masson et al. 1999, Torres et al. 2003). Additionally, DAT is an important target for a variety 
of clinically effective therapeutic drugs, neurotoxic agents, and stimulant drugs of abuse 
(Bannon et al. 1995). DAT proteins are localised to the presynaptic plasma membranes of 
axonal terminals, dendrites, and cell bodies of the dopaminergic neurons. The highest DAT 
levels in the brain are found in the striatum, with much lower levels in the amygdala, 
hippocampus, substantia nigra, and ventral tegmental area (Nirenberg et al. 1996, 1997). 
Because DAT is restricted to only dopaminergic neurons, it provides an excellent 
neurochemical marker for the density and structural integrity of the dopaminergic system. 
Moreover, in vivo imaging (PET and SPECT) of DAT with specific radioligands confirmed 
that these binding sites are affected in several neurodegenerative and psychiatric disorders, 
such as Parkinson’s disease, schizophrenia, and attention-deficit hyperactive disorder 
(ADHD) (Rinne et al. 1999, Laakso and Hietala 2000, Bannon et al. 2005, Varrone and 
Halldin 2010).  
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Several radiotracers, labelled with 11C, 18F or 76Br, have been developed as potential 
candidates for imaging DAT by PET. Cocaine itself binds to DAT with moderate affinity 
(Fowler et al. 1989); however, a number of analogues with potentially higher affinity have 
also been developed based on its tropane moiety. Replacement of the 3?-benzyl group by a 
3?-(4-substituted-phenyl) group has afforded analogues with improved affinity and 
selectivity  to  DAT,  such  as  2?-carbomethoxy-3?-(4-fluorophenyl)tropane ?-CFT (WIN 
35,428) (Clarke 1973), labelled either with 11C (Wong et al. 1993, Dannals et al. 1993) or 18F 
(Haaparanta et al. 1996, Laakso et al. 1998). Furthermore, various radiolabelled derivatives 
having other halide, methyl or fluoromethyl substituent have been developed (Müller et al. 
1993, Farde et al. 1994, Loch et al. 1995, Wilson et al. 1996, Stout et al. 1999). Binding 
potency to DAT was also shown to be affected by the N-substitution of the original tropane 
ring (Emond et al. 1997). Thus, a large number of radiolabelled analogues in which the N-
methyl group is substituted with fluoroethyl (Halldin et al. 1996, Harada et al. 2004, 
Goodman et al. 2000), -propyl (Lundkvist et al. 1995, Chaly et al. 1996, Goodman et al. 
1997, Chaly et al. 1999) or –benzyl groups (Davies et al. 1994, Mach et al. 2000) have been 
developed. Moreover, substitution with an unsaturated chain has resulted in e.g. N-propenyl 
derivatives, such as N-(E)-(3-iodo-prop-2-enyl)-2?-[11C]carbomethoxy-3?-(4-
methylphenyl)nortropane ([11C]PE2I) (Helfenbein et al. 1999, Halldin et al. 2003, Fischman 
et al. 2001). The N-substituted compounds have shown to possess improved selectivity, and 
in  the  case  of  alkenyl  compounds  also  high  affinity  to  DAT.  In  addition,  higher  selectivity  
has been achieved by modification of the 2?-carboxy group into various [18F]fluoroalkyl ester 
congeners (Wilson et al. 1995, Wuest et al. 2007, Mitterhauser et al. 2005, Schou et al. 2009, 
Stepanov et al. 2011) or by adding a [18F]fluoro-2-propoxy substituent. Furthermore, an 
imroved binding potency to DAT was shown for the (S)-isomer of the 18F-labelled 
chlorophenyl tropane 2?-carbo-1-[18F]fluoro-2-propoxy-3?-(4-chlorophenyl)tropane (FIPCT) 
(Xing et al. 2000), although an R-configuration of the tropane ring is typically required for 
biological activity of cocaine analogues (Singh 2000).  
Although structural modifications have lead to compounds with improved binding properties 
to  DAT,  none  of  the  numerous  11C or 18F-labelled cocaine derivatives has shown to be 
optimal for quantitation of DAT by PET. The so called lead compound for DAT ligands, 2?-
carbomethoxy-3?-(4-iodophenyl)tropane (?-CIT) suffers itself from slow kinetics as well as 
poor selectivity (Farde et al. 1994), but its N-fluoroalkylated derivatives N-(3-fluoroethyl)-
2?-[11C]carbomethoxy-3?-(4-iodophenyl)nortropane ([11C]?-CIT-FE) and N-(3-
[18F]fluoropropyl)-2?-carbomethoxy-3?-(4-iodophenyl)nortropane ([18F]FP-CIT) reach peak 
equilibrium more rapidly and also have higher, though still not optimal, selectivity for DAT 
(Halldin et al. 1996, Chaly et al. 1996). ?-CFT has higher selectivity and faster kinetics when 
compared its iodine analogue, however the time to reach binding equilibrium is too slow for 
the quantitation of DAT (Laakso et al. 1998), especially as a 11C-labelled form (Wong et al. 
1993). Therefore, fluoroalkylated derivatives of CFT were developed. PET imaging of the 
monkey brain showed that [18F]?-CFT-FE possesses reversible binding kinetics and 
selectivity for DAT. Furthermore, insensitivity to the anaesthetic effects were reported 
(Harada et al. 2004). In an initial study, the propyl analogue [18F]?-CFT-FP showed 
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accumulation in the rat striatum (Firnau et al. 1995). Selectivity for DAT was further 
demonstrated by autoradiography in post-mortem human brain sections using [11C]?-CFT-FP 
(Kämäräinen et al. 1999, 2000).  
In addition to the slow kinetics and poor selectivity, quantitative PET may be limited due to 
the unfavourable metabolism of phenyl tropanes, mainly arising from N-dealkylation or 
hydrolysis of the 2?-carboxy group (Zoghbi et al. 2006, Ettlinger et al. 2008). Recent interest 
in developing radiotracers for DAT has focused on various N-fluoroalkenyl (e.g. N-(E)-(4-
fluoro-but-2-enyl)-2?-carbomethoxy-3?-(4-methylphenyl)nortropane, LBT-999) (Dollé et al. 
2006a,b, Saba et al. 2007, Stehouwer et al. 2010) and -alkynyl derivatives (Riss et al. 
2009a,b). These so called second generation radioligands have high affinity and selectivity to 
DAT, and also higher resistance to N-dealkylation. Furthermore, modification of the 2?-
carboxy group into the corresponding [18F]fluoroalkyl ester congener has been suggested to 
yield radiotracers with higher in vivo stability (Chitneni et al. 2008, Ettlinger et al. 2008, 
Varrone et al. 2009, 2011). The chemical structure of cocaine and some radiotracers derived 
from it are depicted in Fig. 3. 
 
 
 
Fig. 3. Chemical structure of cocaine and some 18F-radiotracers derived from it by 
following major structural modifications i) replacement of the 3?-benzyl group by a 3?-(4-
substituted-phenyl) group, ii) N-substitution of the tropane ring, iii) modification of the 2?-
carboxy group. [18F]FECT denotes to 2?-carbo-[18F]fluoroethoxy-3?-(4-
chlorophenyl)tropane and [18F]FE-PE2I to N-(E)-(3-iodo-prop-2-enyl)-2?-carbo-
[18F]fluoroethoxy-3?-(4-methylphenyl)nortropane. 
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2.3 Fluorine-18 as a labelling agent for radiopharmaceuticals  
2.3.1. Properties and production of fluorine-18 
18F has several advantages over the other short-lived positron-emitting radionuclides: the 
relatively long T1/2 of 18F (109.8 min) is sufficient for multistep synthesis procedures and/or 
extended imaging protocols; it also allows the transportation of 18F-radiopharmaceuticals 
from  the  production  site  to  imaging  facilities  within  reasonable  distance.  Due  to  the  low  
positron energy (E?+ = 0.63 MeV; maximum range in water 2.4 mm) high spatial resolution 
PET-images can also be achieved and the radiation dose to the patient is minimised. 
Furthermore, 18F can be produced in cyclotrons in large amounts with high specific 
radioactivity, with a theoretical limit of 63 TBq/µmol (1.71 × 106 Ci/mmol) (Kilbourn 1990).  
18F-Labelled radiopharmaceuticals are produced as analogues rather than natural compounds, 
as most biomolecules do not contain fluorine in their structure. 18F is incorporated into the 
molecules as a substituent of a hydrogen atom or a hydroxyl group. The fluorine atom has a 
small steric size but it is very electronegative, therefore, substitution is likely to alter the 
biological properties of the parent compound. Nonetheless, this feature has also been utilised 
in 18F-labelled radiopharmaceuticals, as well as in drug development (Park et al. 2001). In the 
case of glucose analogue 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) (Hamacher et al. 
1986), the substitution of an -OH group with 18F results  in  altered  metabolic  behaviour  and  
the radiopharmaceutical is trapped intracellulary into glucose metabolising cells (Gallagher et 
al. 1978). This phenomenon is utilised in the detection of cancer metastases, in addition to 
other investigations involving changes of cell energy metabolism. Approximately 90% of the 
current clinical PET studies are being performed with [18F]FDG (Coenen et al. 2010).  
18F is can be produced by using cyclotrons to yield either molecular fluorine [18F]F2 or  a  
fluoride ion [18F]F-.  [18F]F2 is typically produced by irradiating a neon gas target with 
medium energy (max 15 MeV) deuterons leading to 20Ne(d,?)18F nuclear reaction (Casella et 
al. 1980). The production method, target design and recovery of [18F]F2, has been modified 
over the years (Quillaume et al. 1991), one example being 18O(p,n)18F reaction on oxygen gas 
targets (Nickles et al. 1984). Nevertheless, production of molecular [18F]F2 requires  the  
addition of 19F2 as a carrier gas leading to poor SA, 0.37-0.74 GBq/µmol (Vallabhajosula 
2009). Only by a special post-target method, conversion of [18F]F- to  [18F]F2, the SA of 
[18F]F2 has been improved up to 55 GBq/µmol (Bergman and Solin 1997). [18F]Fluoride ion 
can be produced with high yield and in a no-carrier-added (NCA) form by proton irradiation 
of 18O-enriched water leading to 18O(p,n)18F nuclear reaction (Ruth and Wolf 1979, Hess et 
al. 2001). By this method SA as high as 5180 GBq/µmol has been achieved (Solin et al. 
1988), a minimum SA level of 185 GBq/µmol is typical in the routine production of [18F]F- 
(Cai et al. 2008).  
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2.3.2. 18F-Labelling methods 
18F is used in radiolabelling reactions in two chemical forms, either the electrophilic [18F]F2 
or the nucleophilic [18F]F-. 18F-Label is introduced into the molecule of interest directly or it 
is coupled to the molecule via 18F-fluorinated prosthetic groups or synthons. In many cases, 
18F-fluorination in a specific position, especially with nucleophilic reactions, requires the 
involvement of protective groups that need to be removed from the molecule resulting in 
multistep synthetic procedures. 
Electrophilic 18F-fluorination is used for introducing 18F into electron-rich substrates such as 
alkenes or aromatic compounds. [18F]F2 can be used directly, however, conversion into 
[18F]acetyl hypofluorite (Visser et al. 1984), [18F]fluoro-N-derivatives or such afford less 
reactive but more selective 18F-labelling reagents. Furthermore, 18F-fluorination with higher 
regioselectivity can be achieved using specific 18F-fluorodemetallation reactions where a 
trialkyltin group, for instance, is replaced with 18F (Adam et  al.  1994).  In  all  reactions,  the  
theoretical maximum radiochemical yield (RCY) is 50%, as only one of the fluorine atoms in 
[18F]F2 is labelled and incorporated into the product. Combined with a poor SA, electrophilic 
18F-fluorination is thus a less popular method for the synthesis of 18F-radiopharmaceuticals. 
Currently, electrophilic 18F-fluorination is mainly utilised in the production of 18F-labelled 
amino acids such as 6-[18F]fluoro-L-dopa and 2-L-[18F]fluorotyrosine (Miller et al. 2008, 
Coenen et al. 2010).  
18F-Fluorination with [18F]F- affords more diverse, though still limited, labelling chemistry; it 
is applicable both for aliphatic bimolecular (SN2) and aromatic (SNAr) nucleophilic 
substitution. Direct nucleophilic 18F-fluorination of aliphatic sulfonate esters or halides, for 
example, is used widely in the production of 18F-radiopharmaceuticals (Snyder and Kilbourn 
2003); the less frequent method is based on ring-opening reactions (Lyle et al. 1987, 
Machulla et al. 2000). Various 18F-labelled radiotracers are also produced by direct 18F-
fluorination of both homo- and heteroaromatic (mainly pyridines) compounds utilising e.g. 
nitro- or trimethylammonium precursors (Ryzhikov et al. 2005, Dollé 2007); one example is 
the production of the serotonin receptor ligand p-[18F]MPPF  (Le  Bars  et  al.  1998).  Direct  
labelling of electron rich arenes can be accomplished by reaction of diaryliodonium salts to 
yield [18F]fluoroarenes (Pike and Aigbirhio 1995). Furthermore, 18F-fluorination by isotopic 
exchange with 19F (e.g. in drug molecules) is possible when high SA is not required, though 
separation of the labelled product typically leads to multi-step procedures (Blom et al. 2009, 
Wagner et al. 2009, Meleán et al. 2010).  
Direct 18F-fluorination is quite often not feasible, therefore, 18F-labelled prostetic groups, 
such as aliphatic 18F-fluoroalkylation, -amidation and –acylation agents, are derived from 
[18F]F-. 18F-Fluoroalkylation agents are typically synthesised by 18F-fluorination of 
corresponding dihalo- or disulfonate alkyl starting materials (Coenen et al. 1986, Block et al. 
1986, 1987), and are subsequently used for labelling of small molecules that possess an 
amino, hydroxyl or thiol group (Kilbourn 1990, Miller et al. 2008), as illustrated in Fig. 4. O- 
and especially N-18F-fluoroalkylation reactions are widely used labelling methods for 18F-
labelled phenyl tropanes for example. [18F]Fluoroethyl tosylate and bromide, as well as their 
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propyl analogues, have all been used in the labelling of 18F-radiotracers directly. 
Alternatively, the 18F-fluoroalkylation reagents have been converted into more reactive 
iodides (Bauman et al. 2003, Dollé et al. 2006b, Klok et al. 2006, Chitneni et al. 2008) or 
triflates in situ (Zhang and Suzuki 2007). Today, [18F]fluoromethylation reagents, especially  
[18F]fluoromethyl bromide, also have value as 18F-labelling agents (Bergman et al. 2001, 
Zessin et al. 2001, Solin et al. 2004, Zheng and Berridge 2000, Iwata et al. 2002, Neal et al. 
2005). The [18F]fluoromethyl group is often unstable in vivo, however, replacement of one or 
two hydrogens with deuterium atoms have shown improved stability (Schou et al. 2004). 
Small 18F-fluoroaromatic compounds can be produced via compounds such as 
[18F]fluorobenzaldehydes and their [18F]fluorobenzyl halide derivatives; labelling of 
macromolecules (peptides, proteins) is typically accomplished by more complex labelling 
agents intended for reaction at amino, carboxylate or thiol function of the molecule (Wuest 
2007, Wester and Schottelius 2007).   
In addition to the above mentioned traditional radiofluorination techniques, novel strategies 
for introducing fluorine-18 into tracer molecules have been established in recent years, such 
as enzymatic 18F-fluorination (Martarello et al. 2003, Deng et al. 2006) and the so called 
“click chemistry” in which 1,3-dipolar cycloaddition reaction between an azide and a 
terminal alkyne (acetylene) is utilised to form corresponding triazoles (Rostovtsev et al. 2002, 
Marik and Sutcliffe 2006). A novel approach replacing the traditional fluorine-carbon 
chemistry with incorporation of [18F]fluorine–silicon, -boron or –phosphorus bonds and 
utilisation of simple halogen-exchange reactions may also lead to more versatile 18F-labelling 
chemistry in the near future (Rosenthal et al. 1985, Ting et al. 2005, Schirrmacher et al. 2006, 
Studenov et al. 2005).  
 
 
 
Fig. 4. Schematic drawing on synthesis and reaction of simple 18F-fluoroalkylation reagents 
 
2.3.3. Important aspects of nucleophilic 18F-fluorinations 
The first requirement for working with [18F]F- is the removal of [18O]water and dissolving the 
dry reagent in an organic solvent. In water [18F]F- is strongly hydrated and thus inactivated 
for nucleophilic reactions, although recently it has been reported that nucleophilic 18F-
fluorinations in ionic liquids have tolerance to water and could therefore be accomplished 
without drying (Kim D. W. et al. 2003, Kim H. W. et al 2004). The state-of-the-art method 
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for obtaining reactive [18F]F- involves adsorption of [18F]F- onto an ion-exchange cartridge 
and subsequent elution with a weak base, typically potassium carbonate (K2CO3), in 
acetonitrile/water solution which is then dried carefully by azeotropic evaporation (Schlyer et 
al. 1990, Cai et al. 2008, Miller et al. 2008). Addition of a phase transfer catalyst, such as 
4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (Kryptofix or K 2.2.2), in the 
mixture enables subsequent solubilisation in organic solvents as a K 2.2.2/[18F]KF complex. 
In this reactive species, K 2.2.2 chelates the counter-cation and separates it from [18F]F-, thus 
enhancing its nucleophilicity (Hamacher et al. 1986). Alternatively, large cations such as 
cesium (Cs+) or tetrabutyl ammonium (tBu4N+) can be applied (Jewett et al. 1998).   
Anionic [18F]F- is very easily protonated, thus, to maintain its reactivity for nucleophilic 
substitution reactions various parameters should be considered: starting materials and 
reagents can not be sources of protons, and weakly basic conditions are preferred (Kilbourn 
1990). In addition, metal salts, as well as most organic substrates, have high solubility in 
polar solvents. Generally it is considered that SN reaction rates are enhanced in the aprotic 
environment (March 1992), thus, most nucleophilic 18F-fluorinations are carried out in polar 
aprotic solvents such as CH3CN, DMF or DMSO (Snyder and Kilbourn 2003).  
Structure of the starting material has great importance in nucleophilic 18F-fluorinations. In 
aliphatic reactions [18F]F- attacks the backside of an electron-deficient site of the molecule, 
resulting in an inversed configuration of the 18F-labelled product, and a suitable leaving group 
with a weak bond to the ? carbon is detached simultaneously. Halides (chloride, bromide or 
iodide) and particularly sulfonate esters (e.g. triflate, mesylate, tosylate or nosylate) are 
effective leaving groups for SN2 reactions. 18F-Fluorinations of these compounds typically 
proceed well, with high incorporation yield (ICY), under relatively mild reaction conditions 
(80-120 °C, 10-20 min), though higher reactivity, that is leaving group ability, may also 
increase the risk of possible competing side reactions such as elimination (Kilbourn 1990, Cai 
et al. 2008). Recently, novel nucleophile assisting leaving groups were introduced for 
enhancing aliphatic 18F-fluorinations with [18F]KF. These arylsulfonates contain a metal 
chelating unit which stabilises the charge in the transition state of the reaction. In comparison 
to conventional leaving groups, higher RCYs were achieved in the absence of cryptand (Lu et 
al. 2009).  
In SNAr reactions, the rate determining step is the attack of the nucleophile and there is less 
influence of the leaving group ability when compared to SN2 reactions (March 1992). 
Nevertheless, a good leaving group, e.g. a nitro- or trimethylammonium group, located at an 
o- or p-position to at least one activating substituent such as a nitro group or carbonyl moiety 
is required. Moreover, successful aromatic 18F-fluorination is typically accomplished under 
harsher reaction conditions, thus using high reaction temperatures and therefore high boiling 
point polar solvents (DMF, DMSO) (Berridge et al. 1985, Shen et al. 2009).  
Various new technologies have also been developed to enhance labelling synthesis with 
[18F]F-. One of these technologies is the use of microwaves. Microwave heating has been 
utilised both in drying procedures for [18F]F- as well as in various 18F-fluorination reactions to 
make labelling reactions faster, more efficient (improved RCY, less decomposition) and in 
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some cases even more selective (Elander et al. 2000, Stone-Elander and Elander 2002, 
Lazarova et al. 2007). In comparison to conventional thermal heating, microwave reactions 
have also afforded the possibility to use a lower amount of inactive starting materials 
(Lemaire et al. 1991). Examples of microwave enhanced reactions can be found both in direct 
aromatic (Le Bars et al. 1998, Vandecapelle et al. 2004) and aliphatic 18F-fluorinations (Riss 
and  Roesch  2009),  as  well  as  in  18F-fluoroalkylation reactions (Lu et al. 2004). Two more 
recent technologies, the utilisation of solid-phase reactions (trapping of [18F]F- or the inactive 
precursor onto polymer support) (Toorongian et al. 1990) and miniaturisation of the synthesis 
(micro-reactors or chips), have already shown their benefits in the purification of the final 
product as well as automation of the radiosynthesis (Gillies et al. 2006, Steel et al. 2007). 
 
2.3.4. Protic solvents in fluorination reactions 
Protic solvents have traditionally been considered as poor reaction media for nucleophilic 
fluorinations as they can reduce fluoride reactivity by hydrogen bonding (March, 1992). 
However, recently there have been studies showing that tert-alcohols, and later bis-terminal 
hydroxy polyethers (Kim et al. 2006, 2008, Lee J. W. et al. 2009) can enhance the reactivity 
of alkali metal fluorides. Quantum chemical analysis of the SN2 reaction [F- + C3H7OMs  ? 
C3H7F + OMs-] in tert-butyl alcohol showed that the relative activation energy barrier of the 
reaction was almost as low as in CH3CN. It was found that F- exhibited limited interactions 
with acidic –OH groups of bulky solvents (degree of solvation) and could therefore create a 
catalytic effect on the SN2 reaction (Lee S.S. et al. 2008). In the study, F- was treated as free 
F- (without a cation), simulating the conditions where interactions with cation have been 
minimised using cyptands or bulky cations. In the presence of a cation, mechanistic studies 
showed that some solvent –OH groups can act as a Lewis base and actually interact with the 
cation and reduce its unfavorable Coulombic interaction with the nucleophile (Oh et al. 2007, 
Im et al. 2009). A new type of mechanism was reported in which fluoride reacts as an ion-
pair with its counter-ion. Protic solvents can promote this type of reaction when affecting 
together  with  a  bulky  and  polarisable  cation,  such  as  Cs+ (Oh  et  al.  2007).  In  recent  
mechanistic studies this advantage was reported also for nucleophilic aromatic substitution 
reactions (Park et al. 2010). 
Besides the activation of fluoride, two other advantages of the protic environment have been 
reported, namely the possible hydrogen bonding with the leaving group (i.e. the oxygen 
atoms of aliphatic sulfonate or aromatic nitro-group) and other reactive heteroatoms in the 
substrate (Kim et al. 2008, Oh et al. 2007, Park et al. 2010). These interactions would 
improve nucleophilic fluorination by enhancing the leaving group ability and reducing 
unwanted side reactions. The possible catalytic effects of protic solvent, together with a 
counter-cation, are illustrated in Fig. 5.  
Although the previously reported studies have demonstrated the advantage of using tert-
alcohols  in  nucleophilic  fluorination,  so  far  there  are  few  studies  where  protic  solvents  are  
systematically examined in tracer conditions (pmol-nmol) using [18F]F-.  Radiolabelling of a 
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thymidine analogue 3’-deoxy-3’-[18F]fluorothymidine ([18F]FLT) has been investigated more 
profoundly. It was shown that 18F-fluorination with tetrabutylammonium [18F]fluoride 
([18F]TBAF) in tert-alcohols afforded higher radiochemical yields in mild reaction conditions 
when compared to previously reported conventional methods in aprotic solvents (Kim et al. 
2006, Lee S. J. et al. 2008). Successful 18F-fluorination in t-BuOH was  achieved  both  with  
tBu4N+ and  Cs+ as a counter cation for [18F]F-, however the conventional phase transfer 
system K 2.2.2/[18F]KF was not tested (Lee S. J. et al. 2007a). In this study Cs+ cation was 
used in the presence of cryptand (K 2.2.2), nevertheless, optimisation of the method to an 
automated module showed that radiofluorination using tBu4N+ cation resulted eventually in 
better yields (Kim et al. 2006, Lee S. J. et al. 2007a). 18F-Fluorination of the sulfonate ester 
group in a structurally different starting material for [18F]FLT, however, was not promoted by 
the similar synthetic conditions (tetrabutylammoniumbicarbonate, t-BuOH) (Windhorst et al. 
2008). Recently protic solvents were utilised also in aromatic 18F-fluorination: labelling of an 
aromatic trimethylammonium precursor was accomplished equally well, both in CH3CN and 
a protic solvent mixture (CH3CN:t-BuOH; 2:8) using very mild reaction conditions (40 ºC, 10 
min). Some desired 18F-labelled product was achieved with the KHCO3-K 2.2.2. system and 
the  RCYs were  improved  when the  cation  was  changed  to  the  bulkier  tBu4N+. The leaving 
group in this nicotinic acid derivative was highly activated by the pyridine ring as well as by 
the tetrafluorophenyl ester moiety (Olberg et al. 2010).  
 
 
 
 
Fig. 5. Schematic drawing of the possible interactions between the solvent, the nucleophile 
and the target molecule in the SN2 reaction.   
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3. AIMS OF THE STUDY 
 
The general aim of this study was to investigate the feasibility of various nucleophilic 18F-
fluorination strategies for production of 18F-labelled compounds.  
 
The specific aims of the study were: 
 
1. to provide information on the effect and suitability of protic solvents for 18F-labelling 
reactions in comparison to conventional aprotic solvents 
2. to evaluate different radioanalytical methods, radio-TLC, -HPLC and –MS, for the 
assessment of 18F-fluorinated products  
3. to optimise the overall radiosynthesis procedure for the cocaine analogue ?18F??-CFT-
FP in terms of radiochemical yield and quality of the final product 
4. to evaluate ?18F??-CFT-FP as a novel radiotracer for imaging DAT by determining its 
biodistribution ex vivo in rats 
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4. MATERIALS AND METHODS  
 
4.1. Synthesis and identification of starting materials and fluorinated reference 
compounds 
The starting material for p-[18F]MPPF, 4-nitro-N-[2-[1-(methoxyphenyl)-1-piperazinyl]ethyl-
N-2-pyridinyl-benzamide (p-MPPNO2) and the corresponding fluorinated reference 
compound, 4-fluoro-N-[2-[1-(methoxyphenyl)-1-piperazinyl]ethyl-N-2-pyridinyl-benzamide 
(p-MPPF), were kindly supplied by Professor Christer Halldin from the Karolinska Institute, 
Stockholm, Sweden. Starting materials and the reference compound for radiolabelled ?-CFT-
FP were synthesised at the Department of Chemistry, University of Kuopio, Finland. 
Syntheses  of  2?-carbomethoxy-3?-(4-fluorophenyl)nortropane ?nor-?-CFT), N-(3-
fluoropropyl)-2?-carboxylic acid-3?-(4-fluorophenyl)nortropane ??-CFT-FP-acid) and N-(3-
fluoropropyl)-2?-carbomethoxy-3?-(4-fluorophenyl)nortropane ??-CFT-FP) are described in 
the original paper (III). The synthesis of N-(3-tolylsulfonyloxypropyl)-2?-carbomethoxy-3?-
(4-fluorophenyl)nortropane ?Tos-?-CFT-FP) was based on alkylation of nor-?-CFT with  3-
bromo-propanol in the presence of a base to produce the corresponding hydroxypropyl 
compound OH-?-CFT-FP, and the subsequent reaction with toluenesulfonic anhydride for the 
preparation of Tos-?-CFT-FP. Details of syntheses for 4-(R1-methyl)benzyl R2-benzoates are 
described in the original paper (I), except for the additional starting and reference materials 
that are given below.  
Reagents and solvents were purchased from commercial suppliers and anhydrous reagents 
were used without extra drying. The non-radioactive compounds were characterised mainly 
by 1H NMR spectroscopy, the spectra were recorded on a Varian 300-MR 300 MHz 
spectrometer (Paper I) or a Bruker AM 400 WB spectrometer (Paper III), at 25 °C. Chemical 
shifts were referenced to residual protons in solvent: tetramethyl silane (TMS)=0.0 ppm. 
Elemental analysis, with Elementar VarioMICRO cube system, was used as an additional 
method for verifying the purity of the starting materials and reference compounds for 4-(R1-
methyl)benzyl para-R2-benzoates. The inactive precursor p-MPPNO2 and the product 
reference p-MPPF were also analysed by mass spectrometry using a Bruker Daltonics 
Esquire 3000 instrument with an electron spray ionisation-Ion trap MSn System (ESI-MS).  
 
4.1.1. Synthesis of 4-(R1-methyl)benzyl 2-R2-benzoates 
Benzylic compounds were synthesised by esterification of corresponding 2-chloro or 
iodobenzoyl chloride in the presence of base, as depicted in Scheme 1. Halogenated 
compounds were synthesised by the reaction with 4-(chloromethyl)benzyl alcohol; 1,4-
bis(hydroxymethyl)benzene was used to produce corresponding hydroxyl compounds. 
Reactions proceeded for 4 hours at room temperature (RT). Products were purified by flash 
column chromatography on silica gel with mesh 200-400 using CH2Cl2:hexane (1:1; for 
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halogenated compounds) or CHCl3:EtOAc (2:1; for hydroxyl compounds). The separated 
products were dried under reduced pressure. 
4-(chloromethyl)benzyl 2-chlorobenzoate (o-activated starting material) was synthesised 
from 2-chlorobenzoyl chloride (115 µL, 158 mg, 0.91 mmol), 4-(chloromethyl)benzyl 
alcohol (204 mg, 1.29 mmol) and triethylamine (TEA) (210 µL, 152 mg, 1.50 mmol). 
Purification (retardation factor Rf = 0.37) gave 263 mg (0.89 mmol, 98%) of the title 
compound as a colourless oil. 1H NMR (300 MHz, CDCl3, 25 ºC): ? = 7.9 (m, 1H, Ph), 7.4 
(m, 6H, Ph), 7.3 (m, 1H, Ph), 5.4 (s, 2H, CH2), 4.6 (s, 2H, CH2-Cl) ppm. 
4-(chloromethyl)benzyl 2-iodobenzoate (o-activated starting material) was synthesised 
from 2-iodobenzoyl chloride (258 mg, 0.97 mmol), 4-(chloromethyl)benzyl alcohol (402 mg, 
2.54 mmol) and TEA (470 µL, 341 mg, 3.38 mmol). Purification (Rf = 0.50) gave 280 mg 
(0.72 mmol, 74%) of the title compound as a white solid. 1H NMR (300 MHz, CDCl3, 25 ºC): 
? = 8.0 (m, 1H, Ph), 7.8 (m, 1H, Ph), 7.5 (m, 1H, Ph), 7.4 (m, 4H, Ph), 7.1 (m, 1H, Ph), 5.4 
(s, 2H, CH2), 4.6 (s, 2H, CH2-Cl) ppm. 
4-(hydroxymethyl)benzyl 2-chlorobenzoate (starting material for 4-(fluoromethyl)benzyl 2-
chlorobenzoate) was synthesised from 4-chlorobenzoyl chloride (100 µL, 138 mg, 0.79 
mmol), 1,4-bis(hydroxymethyl)benzene (350 mg, 2.46 mmol) and TEA (400 µL, 290 mg, 
2.87 mmol). Purification (Rf = 0.50) gave 169 mg (0.61 mmol, 77%) of the title compound as 
a white solid. 1H NMR (300 MHz, CDCl3, 25 ºC): ? = 7.8 (m, 1H, Ph), 7.4 (m, 7H, Ph), 5.4 
(s, 2H, CH2), 4.7 (s, 2H, CH2-OH), 1.7 (s, 1H, OH) ppm.  
4-(hydroxymethyl)benzyl 2-iodobenzoate (starting material for 4-
(methylsulfonyloxymethyl)benzyl 2-iodobenzoate) was synthesised from 2-iodobenzoyl 
chloride (1 g, 3.75 mmol), 1,4-bis(hydroxymethyl)benzene (1.48 g, 10.7 mmol) and TEA (2.0 
ml, 1.45 g, 14.4 mmol). Purification (Rf = 0.54) gave 87 mg (0.24 mmol, 63%) of the title 
compound as a white solid. 1H NMR (300 MHz, CDCl3, 25 ºC): ? = 8.0 (m, 1H, Ph), 7.8 (m, 
1H, Ph), 7.5 (m, 1H, Ph), 7.4 (m, 4H, Ph), 7.1 (m, 1H, Ph), 5.4 (s, 2H, CH2), 4.7 (d, JH,OH = 
3.6 Hz, 2H, CH2-OH, ), 1.7 (s, 1H, OH) ppm.  
 
 
 
Scheme 1. Synthesis of 4-(R1-methyl)benzyl 2-R2-benzoates  
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Hydroxyl compounds were subsequently used to synthesise fluorinated reference compounds. 
Alternative methods were the production of corresponding mesylate ester and subsequent 
fluorination with cesium fluoride (CsF), or direct reaction with (diethylamino)sulphur 
trifluoride (DAST), as depicted in Scheme 2.  
4-(methylsulfonyloxymethyl)benzyl 2-iodobenzoate (starting material for 4-
(fluoromethyl)benzyl 2-iodobenzoate) To 4-(hydroxymethyl)benzyl 2-iodobenzoate (180 mg, 
0.49 mmol) in anhydrous CH2Cl2 (5 mL) was added methanesulfonic anhydride (160 mg, 
0.92 mmol) and dropwise TEA (1.5 ml, 1.09 g, 10.8 mmol) at 7 °C. The mixture was stirred 
for  10  minutes  at  RT under  argon  (Ar)  atmosphere.  The  reaction  was  quenched  with  water  
(40 mL, 4 °C) and the mixture was extracted with CHCl3 (4×20 mL). The organic phase was 
dried over Na2SO4 and evaporated to dryness. The residue was purified by column 
chromatography (silica gel, mesh 200-400) with CHCl3:EtOAc  (2:1,  Rf =  0.70).  The  
separated product was dried under reduced pressure to give 109 mg (0.24 mmol, 49%) of the 
title compound as a white solid. 1H NMR (300 MHz, CDCl3, 25 ºC): ? = 8.0 (m, 1H, Ph), 7.8 
(m, 1H, Ph), 7.5 (m, 1H, Ph), 7.4 (m, 4H, Ph), 7.1 (m, 1H, Ph), 5.4 (s, 2H, CH2), 5.3 (s, 2H, 
CH2), 2.9 (s, 3H, OSO2CH3) ppm.  
4-(fluoromethyl)benzyl 2-iodobenzoate (fluorinated reference compound) Anhydrous CsF 
(169 mg, 1.10 mmol) and 4-(methylsulfonyloxymethyl)benzyl 2-iodobenzoate (70 mg, 0.20 
mmol) were dissolved in t-amyl alcohol (3 mL) and mixed at 80 °C for 2.5 hours. Diethyl 
ether was then added in portions (total 50 mL) into the reaction mixture. The organic phase 
was filtered and evaporated under reduced pressure. The residue was purified by column 
chromatography (silica gel, mesh 200-400) with hexane:CH2Cl2 (1:1,  Rf = 0.32) and the 
separated product was dried under reduced pressure to give 30 mg (0.07 mmol, 35%) of the 
title compound. 1H NMR (300 MHz, CDCl3, 25 ºC): ? = 8.0 (m, 1H, Ph), 7.8 (m, 1H, Ph), 7.5 
(m, 1H, Ph), 7.4 (m, 4H, Ph), 7.1 (m, 1H, Ph), 5.4 (d, JH,F = 47.7 Hz, 2H, CH2-F), 5.3 (s, 2H, 
CH2) ppm.  
4-(fluoromethyl)benzyl 2-chlorobenzoate (fluorinated reference compound)  4-
(hydroxymethyl) benzyl 4-chlorobenzoate  (80 mg, 0.29 mmol) was dissolved in anhydrous 
CH2Cl2 (5  mL)  under  Ar  atmosphere.  The  reaction  vial  was  placed  in  an  ice  bath  and  
(diethylamino)sulphur trifluoride (DAST) (60 µL, 73 mg, 0.45 mmol) was added dropwise. 
The mixture was stirred (under Ar atmosphere at 0 ºC) for 15 min. The reaction was stopped 
by slowly adding cold, saturated NaHCO3 (10 mL). The crude mixture was extracted with 
CH2Cl2 (5×20 mL). The organic phase was dried over Na2SO4, filtered and evaporated to 
dryness. The residue was purified by column chromatography (silica gel, mesh 200-400) with 
CH2Cl2:hexane (2:1, Rf = 0.38) and the separated product was dried under reduced pressure 
to give 67 mg (0.24 mmol, 83%) of the title compound as  a  colourless  oil.  1H NMR (300 
MHz, CDCl3, 25 ºC): ? = 7.9 (m, 1H, Ph), 7.4 (m, 6H, Ph), 7.3 (m, 1H, Ph), 5.4 (d, JH,F = 
47.4 Hz, 2H, CH2-F), 5.3 (s, 2H, CH2) ppm.  
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Scheme 2. Synthesis routes for fluorinated reference compounds 4-(fluoromethyl)benzyl 2-
R2-benzoates  
 
4.2. Radiosyntheses in general  
No-carrier-added [18F]F- was produced by 18O(p,n)18F nuclear reaction on 18O-enriched 
??95%) water (Ruth and Wolf 1979) using either 10 MeV protons produced with an IBA 
Cyclone® 10/5 cyclotron at the Laboratory of Radiochemistry, University of Helsinki (Papers 
I-II, IV-V), or 16 MeV protons with a Scanditronix RNP 16 cyclotron at the Karolinska 
Hospital, Stockholm (Paper III). In addition, 11C was produced as ?11C?carbon dioxide 
utilising 14N?p,?)11C nuclear reaction on nitrogen (Christman et al. 1975) (Paper III). Origin 
of the non-radioactive starting materials and fluorinated reference compounds are described in 
paragraph 4.1. Other reagents and chemicals were obtained from commercial sources. HPLC-
solvents were of HPLC grade and other chemicals were of analytical grade.  
In all 18F-fluorination studies, reactive [18F]F- was produced by the well known method, 
azeotropic distillation (110-120 ?C, typically under a nitrogen stream) from added base 
(K2CO3) and cryptand (K 2.2.2) (Hamacher 1986). Radiosynthesis of ?18F??-CFT-FP was 
carried out without recovery of the target water, thus 18F-radioactivity was added straight into 
a solution containing K 2.2.2 and K2CO3 in CH3CN. For radiolabelling of p-[18F]MPPF, the 
aqueous [18F]F- was first trapped onto an anion exchange cartridge (Chromafix® PS-HCO3, 
Macherey-Nagel) from which it was eluted with K2CO3–solution to a reaction vial containing 
K 2.2.2 in anhydrous CH3CN.  Another  SPE  cartridge,  a  Waters  Sep-Pak®  Light  QMA  
(QMA), was used in 18F-fluorination of 4-(R1-methyl)benzyl R2-benzoates: [18F]F- was eluted 
from the cartridge with a CH3CN solution containing K 2.2.2, K2CO3 and H2O. The reaction 
mixture was subsequently dried carefully. Produced ?11C?CO2, trapped in a cooled (liquid 
nitrogen) stainless steel coil, was first converted to ?11C?methyl iodide and subsequently 
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passed through a heated soda glass column (170 ºC) containing silver triflate impregnated 
graphitised carbon to produce ?11C?methyl triflate, as described elsewhere (Halldin et al. 
1990, Jewett et al. 1992). Radiosyntheses were performed in remote-controlled semi-
automated synthesis modules when possible. In the microwave experiments, a Resonance 
Instrument Model 520A oven was used (Paper II). Radioactivity of labelled samples was 
measured in an isotope calibrator.  
The radiolabelled ?-CFT-FP and p-[18F]MPPF were purified by a reversed-phase HPLC. In 
general the semi-preparative HPLC system consisted of a HPLC pump, an injector (with 1-2 
mL injection loop) and a UV detector (set for 254 or 270 nm) in series with a radioactivity 
detector. Semi-preparative C18 HPLC columns were used; details of the chromatographic 
conditions  are  described  in  the  original  papers  or  alternatively  under  the  description  of  the  
labelling method. The collected product fraction was evaporated to dryness and the residue 
was dissolved in 0.9% NaCl to give the formulated, final product.  
 
4.3. Radiolabelling of 4-(R1-methyl)benzyl R2-benzoates (I) 
A  series  of  4-(R1-methyl)benzyl R2-benzoates 1-5, with a potential group for direct 
substitution with [18F]F- either at benzylic (R1) or aromatic position (R2), were labelled using 
the K 2.2.2/[18F]KF phase transfer system, Scheme 3. Substitution reactions were carried out 
in t-BuOH and t-amyl  alcohol  as  well  as  in  CH3CN and DMF; the CH3CN:co-solvent ratio 
was 2:8. In addition, 18F-fluorination in tert-alcohols was studied by varying the activation 
system for [18F]F-: compounds 2a (R1 = Cl) and 5 (R2 = p-NO2) were labelled using [18F]CsF, 
with and without K 2.2.2, at 120 ºC.  
 
 
Scheme 3. Radiofluorination of 4-(R1-methyl)benzyl R2-benzoates resulting in either a) 
aliphatic or b) aromatic 18F-fluorination 
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4.4. Radiolabelling of p-MPPF (II) 
Radiosynthesis of p-[18F]MPPF was based on direct nucleophilic substitution of 
corresponding nitro-precursor with [18F]F-,  Scheme 4.  p-MPPNO2 in anhydrous DMSO was 
added to the dry K 2.2.2/[18F]KF complex and the reaction mixture was heated in an oil bath 
(150-180 ?C for 5-20 min) or using a microwave oven (40 W for 3 × 20 s). The method was 
modified slightly from Le Bars et al. (Le Bars et al. 1998), solvent exchange by SPE prior to 
HPLC purification was excluded from the synthesis procedure. 
 
 
 
Scheme 4. Radiosynthesis of p-[18F]MPPF starting from p-MPPNO2 
 
4.5. Radiolabelling of ?-CFT-FP  
4.5.1. Labelling with 11C (III) 
?11C??-CFT-FP was synthesised by esterification of corresponding carboxylic acid precursor 
with ?11C?methyl triflate (Någren et al. 1995, Lundkvist et al. 1998), Scheme 5a. The labelling 
reagent was trapped over 3-4 min into a closed reaction vial containing ?-CFT-FP-acid, 
acetone and freshly prepared aqueous tetrabutylammonium hydroxide (TBAOH). 
 
4.5.2. Direct nucleophilic 18F-fluorination (unpublished method) 
Production of [18F]?-CFT-FP was studied by direct 18F-labelling of corresponding 
toluenesulfonyl ester, Tos-?-CFT-FP,  Scheme  5b.  The  reaction  mixture  containing  NCA  
aqueous [18F]F-, K 2.2.2 ?15 mg, 0.040 mmol) and K2CO3 ?3 mg, 0.022 mmol) in CH3CN 
?300 ?L) was dried carefully by azeotropic distillation; 1.0 mL of CH3CN was added three 
times during the drying procedure. Tos-?-CFT-FP ?3-9 mg, 0.006-0.019 mmol) in CH3CN 
?300-900 ?L) was added and the reaction mixture was heated at 90 ?C for 20 min (closed 
vial). The reaction mixture was cooled to RT and mobile phase ?0.7 mL) was added. Crude 
[18F]?-CFT-FP was purified by semi-preparative HPLC on a Waters ?Bondapak® C18 column 
(7.8×300 mm, 10 ?m) using 0.01 M H3PO4/CH3CN (78:22; v/v) as an eluent with a flow rate 
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of 4 mL/min. Analytical HPLC was based on similar chromatographic conditions 
(H3PO4/CH3CN; 70:30; 2 mL/min) using an analytical C18 column (3.9×300 mm), radioTLC 
analysis was carried out using silica gel plates and hexane/Et2O/TEA (7:3:1; v/v) as a mobile 
phase. 
 
4.5.3. 18F-fluoroalkylation with [18F]fluoropropyl bromide (III) 
In the two-step procedure, [18F]?-CFT-FP was synthesised by N-18F-fluoroalkylation of nor-
?-CFT with ?18F?fluoropropyl bromide, Scheme 5c, as previously described for the iodinated 
analogue, [18F]?-CIT-FP (Lundkvist et al. 1997). [18F?Fluoropropyl bromide was first 
produced by labelling of 1,3-dibromopropane in CH3CN (110?C for 10 min), and 
subsequently purified by C-18 SPE method and following distillation. The distilled 
?18F?fluoropropyl bromide was trapped into a reaction vial containing nor-?-CFT in DMF, 
with or without base, K2CO3. The vial was sealed and heated at 135 ?C for 10-30 min.  
 
4.5.4. 18F-fluoroalkylation with [18F]fluoropropyl tosylate (III-V) 
In the second 18F-fluoroalkylation method, [18F]fluoropropyl tosylate was used as a labelling 
reagent, Scheme 5d. In the first labelling experiments (Paper III) the synthesis procedure was 
similar to the method described above: 1,3-propanediol di-p-tosylate was labelled with K 
2.2.2/[18F]KF (90 ?C for 10 min). The produced labelling reagent was subsequently separated 
from the reaction mixture by SPE and transferred into a reaction vial containing nor-?-CFT. 
The reaction mixture was heated at 120 ?C for 10-30 min.  
In the further optimisation studies (Paper IV), the radiochemical yield of [18F]fluoropropyl 
tosylate was investigated by varying mainly the amount of precursor (2?15 mg) and reaction 
time (10 or 20 min). The SPE purification of the 18F-fluoroalkylation reagent was also studied 
in  more  detail.  In  addition  to  the  C-18  cartridge  and  DMF  as  an  eluent,  SiO2 cartridge 
?Waters Sep-Pak® Plus Silica) was tested with diethylether (Goodman et al. 2000) or 
hexane:diethylether (3:1; v/v) as an eluent (Harada et al. 2004). Finally, dry DMF solution 
containing a variable amount of nor-?-CFT  (2?20  mg)  with  or  without  base,  Cs2CO3, was 
added into the labelling reagent mixture. The reaction vial was sealed and heated at 135 ?C; 
varying the reaction time from 10 to 50 min. Significantly lower and higher reaction 
temperatures were also tested using a 25 min heating time.  
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Scheme 5. Radiolabelling studies of ?-CFT-FP by various routes a-d 
 
4.6. Radioanalytical methods  
All radiolabelled products were analysed by radio-TLC and -HPLC. The identity of the 
desired 18F-labelled product was confirmed by comparing the radiochromatogram with the 
UV-chromatogram of non-labelled reference material. Radiochemical incorporation yield and 
radiochemical purity of the final product was determined mainly by radio-TLC. Analytical 
HPLC was also used to determine the specific radioactivity of [18F]?-CFT-FP (Paper IV). A 
standard curve was generated to calculate the mass of the tracer in the final solution. In 
addition, in order to identify all the labelled products of p-[18F]MPPF radiosynthesis, 
radioactive fractions were collected from the semi-preparative HPLC purification and were 
analysed also by LC-MS (Paper II).  
TLC was carried out using silica gel plates (60 F254). UV visualisation was accomplished 
with a UV-lamp at 254 nm. Radioactivity was detected using a Raytest MiniGita TLC-
scanner (Papers III-V) or digital PSL autoradiography with Fuji Imaging Plates (BAS-
TR2025) and a FujiFilm FLA-5100 scanner (Papers I-II). The imaging system was operated 
by Fujifilm Image Reader Software and data was analysed with an AIDA 2.0 Image 
Analyser. The analytical HPLC was similar to the semi-preparative system, with smaller 
injection loops (100 µL) and analytical C-18 HPLC columns. Details of the chromatographic 
conditions both for TLC and HPLC are described in the original papers or under the specific 
labelling method. 
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The MS studies were performed using a Bruker Daltonics Esquire 3000 instrument with an 
electron spray ionisation-Ion trap MSn System (ESI-MS). The preparative HPLC fractions 
were analysed by a LC-MS technique with an Agilent 1100 liquid chromatography system. 
The radioactivity of the measured fractions was evaluated with a dose rate meter beside the 
inlet of ESI.  
 
4.7. Pre-clinical evaluation of [18F]?-CFT-FP (V) 
Biodistribution of [18F]?-CFT-FP was determined ex vivo in rats. The radiotracer was 
injected into the tail veins of rats (Harlan Sprague-Dawley male) under light anaesthesia. 
After certain time-points, 5, 15, 30, 60, or 120 min, the animals were killed and blood, urine, 
and organs were removed, weighed, and measured for 18F-radioactivity (Bicron NaI(Tl) well 
counter). The brain regions to be examined, striatum, frontal cortex, and cerebellum, were 
dissected, weighed, and measured for 18F-radioactivity. Radioactivity data was decay-
corrected to the time of injection and the uptake of 18F-radioactivity in all organs and tissues 
was expressed as a percentage of the injected radioactivity dose (ID) per gram of tissue 
(%ID/g).  
The DAT selectivity of ?18F??-CFT-FP in brain was assessed by pre-treatment with a highly 
selective DAT inhibitor GBR12909. GBR12909 (5 mg/kg; dissolved in H2O:0.9% NaCl, 
50:50, v/v) was injected intravenously in rats 60 min prior to the injection of ?18F??-CFT-FP. 
The regional distribution of the 18F-radioactivity in the brain of control and GBR12909 pre-
treated rats at 15 min after injection of the radioligand was determined using digital 
autoradiography. The brains were frozen in isopentane chilled with dry ice for sectioning 
with a cryomicrotome at -15 ?C. Coronal brain sections (20 µm) were thaw-mounted onto 
microscope slides, air dried, and apposed to an imaging plate (Fuji BAS-TR2025) for 4 h. 
The imaging plates were scanned with the Fuji Analyzer BAS-5000.  
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5. RESULTS  
 
5.1. 18F-Fluorination of benzyl derivatives in various solvents (I, unpublished data) 
18F-Fluorination of 4-(R1-methyl)benzyl R2-benzoates 1-3 with benzylic halide or a mesylate 
leaving group was achieved in all solvents during the 15 minutes reaction time (Scheme 3a). 
CH3CN gave the highest radiochemical yields in all temperatures and good yields were 
already  achieved  in  this  solvent  at  80  °C,  as  presented  in  Table  2.  In  protic  solvents,  18F-
fluorination yields of the benzyl halides (1-2) were improved when the reaction temperature 
was  increased;  however,  RCYs  comparable  to  CH3CN were accomplished only with 
compound 3. For this mesylated material, good yields were already achieved at the lowest 
reaction temperature for both t-BuOH and t-amyl  alcohol  and  the  RCY  peaked  at  120  °C.  
Comparison of decay-corrected RCYs in different solvents for 18F-fluorination of 1a and 3 is 
depicted in Fig. 6. 
Aromatic 18F-fluorination was not promoted by the tert-alcohols, and no 18F-fluorinated 
product was formed from either of the starting materials even at the highest temperature. 
Instead, compound 5 having a para-activated nitro group as a leaving group, was successfully 
18F-fluorinated in DMF and with low yield in CH3CN (Scheme 3b). The highest 
radiochemical yields with both solvents were achieved at 160 °C (Table 2).  
 
 
 
 
Fig. 6. Dependence  of  RCY (%±SD,  n?3)  on  the  solvent  and  reaction  temperature  in  18F-
fluorination of a) compound 1a (R1=Cl) and b) compound 3 (R1=OMs).  
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Table 2. Radiochemical yield of 18F-fluorination reactions with K 2.2.2/[18F]KF in different 
solvents and reaction temperatures. 
 Starting material 18F-
labelled 
product 
T [ºC]a RCY [%]b in different solventsc 
    t-BuOH t-amyl 
alcohol 
CH3CN DMF 
        
1a 
 
[18F]6a 80 3.0±0.2 4.9±0.5 80.9±3.2 30.8±19.1 
  120 34.9±7.3 37.6±2.5 88.7±2.6 32.4±7.3 
  160 49.1±9.1 49.6±0.2 83.6±4.8 78.3±4.9 
        
 
 
      
1b [18F]6b 80 2.1±0.8 1.6±0.2 70.3±3.8 30.3±1.1 
  120 29.9±2.3 13.4±2.0 76.8±8.2 42.8±4.8 
  160 65.1±3.0 27.7±2.0 76.3±1.6 65.3±1.6 
       
        
        
2a 
 
[18F]7a 80 0.8±0.2 1.6±0.2 44.6±4.4 18.9±3.2 
  120 13.3±6.2 25.1±2.6 71.5±0.6 36.9±3.5 
  160 18.7±6.4 51.5±10.0 66.2±6.5 56.2±2.0 
        
        
 
 
      
2b [18F]7b 80 0.7±0.3 1.2±-- 49.2±6.5 7.5±0.8 
  120 9.5±1.9 17.1±4.0 83.6±2.4 23.3±4.7 
  160 25.5.±6.2 24.5±-- 73.4±1.3 52.4±23.1 
       
        
        
3 
 
[18F]7a 80 53.2±4.7 69.8±2.3 86.7±1.1 26.9±10.7 
  120 74.4±3.4 73.3±9.3 85.3±1.8 46.7±3.0 
  160 72.3±2.1 72.0±9.9 88.3±1.3 56.0±6.1 
        
        
4 
 
no 80-160 0 - 0 0 
 reaction      
       
        
        
5 
 
[18F]8 80 0 0 0 1.2±0.1 
  120 0 0 2.5±0.7 15.0±1.2 
  160 0 0 5.9±1.9 19.9±2.6 
       
 
 
Labelled products [18F]6 and  [18F]7 stand  for  [18F]fluorination on benzylic position and [18F]8 on aromatic position, no 
reaction occurred with compound 4. 
a Temperature of the heating bath 
b The total overall radiochemical yield (%±SD, n?3).  
c Reaction conditions: a closed vial containing 1.5 µmol of starting material in 0.3 mL of solvent (23% of CH3CN added 
in all solvents for better solubility), reaction time 15 min.  
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Formation of 18F-labelled side-products during the 18F-fluorination of 1-3 was strongly 
dependent on the solvent and reaction temperature, as presented in Fig. 7. In polar aprotic 
solvents, only a minor number of side-products were formed. However, when the tert-
alcohols were used, the percentage of radiolabelled side-products was increased along with 
the reaction temperature. It was also found that when starting materials with an activating 
ester group in o-position (compounds 1b and 2b) were labelled in similar reaction conditions, 
a smaller amount of labelled side-products were formed than with p-activated compounds. 
Using compounds 4 and 5 the formation of labelled side-products was less significant.  
 
 
 
Fig. 7. Radio-TLC analysis of 18F-fluorination of compound 2a in a) CH3CN and b) t-BuOH 
at different reaction temperatures. (Silica plate, CH2Cl2:hexane, 2:1).  
 
In order to study the effect of [18F]F- activation on SN2 and SNAr reaction yields, compounds 
2a (R1=Cl) and 5 (R2=NO2) were also labelled with [18F]CsF in protic solvents. Changing the 
counter-cation from K+ to Cs+ and leaving out K 2.2.2, resulted in a significant loss of [18F]F- 
on  the  walls  of  the  reaction  vial,  and  subsequently  no  reaction  occurred.  Applying  the  
cryptand  did  not  improve  the  solubility  of  [18F]CsF when t-amyl alcohol was used. In t-
BuOH the presence of K 2.2.2 improved the solubility of [18F]CsF to some extent, however, 
the radiochemical incorporation yield of [18F]7a was nevertheless lower when compared to 
yield with [18F]KF. Results from the 18F-fluorination of compound 2a in t-BuOH with 
different activation systems for [18F]F- are presented in Table 3. Labelling of compound 5 
with K 2.2.2/[18F]CsF resulted in no 18F-fluorinated product. 
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Table 3. 18F-Fluorination of compound 2a in t-BuOH using different activating systems for 
[18F]F-. 
Origin of 18F-radioactivity 
in the reaction mixture 
ICY[%]a with different counter cations  
 K+ with K 2.2.2b Cs+ without K 2.2.2c Cs+ with K 2.2.2d 
Unreacted [18F]F- 76.8±9.2 100 97.1±0.8 
18F-labelled product: [18F]7a 14.1±6.7 - 2.9±0.8 
18F-labelled side-products 9.1±2.5 - - 
 
Labelling reaction conditions: 1.5 µmol of compound 2a in 0.3 mL of t-BuOH (23% of CH3CN added for better 
solubility), 15 min, 120 ºC.  
a Incorporation yield = percentage of total integrated activity in radio-TLC (%±SD, n?2).  
b [18F]F- eluted from QMA cartridge with 2 mL of 6mM K2CO3 solution (contains 9.5 mg of K 2.2.2). 
c [18F]F- eluted from QMA cartridge with 2 mL of 6mM Cs2CO3 solution.  
d [18F]F- eluted from QMA with 2 mL of 6mM Cs2CO3 solution to a vial containing 9.5 mg of K 2.2.2.  
 
 
5.2. Evaluation of p-[18F]MPPF radiosynthesis (II) 
The radiochemical incorporation yield of p-[18F]MPPF using oil bath heating was 27.9±9.5% 
(mean±SD, measured by radio-HPLC). This resulted in 3.7±2.4% overall decay-corrected 
radiochemical yield (mean±SD) for the purified and and 2.5±0.6% for the formulated p-
[18F]MPPF (with radiochemical purity ?95%). The highest ICY of p-[18F]MPPF was reached 
already within 5 minutes reaction time at 170-180 ?C; prolonging the reaction time or using 
lower temperature (150?C) with longer heating time (20 min) did not improve the yield. 
Microwave heating did not increase the radiochemical yield of p-[18F]MPPF either. 
Furthermore, independent of the heating method, significant amounts of labelled side-
products were formed. Radio-HPLC analysis of the crude reaction mixture showed 2-4 
radioactive by-products eluting after p-[18F]MPPF, as depicted in Fig. 8. 
Subsequently, the 18F-labelled products (1-5) were collected from the semi-preparative HPLC 
purification and analysed. In analytical radio-HPLC, the purified p-[18F]MPPF eluted at about 
13.5 min, one major by-product (fraction 2) had a 2-3 min longer retention time, and the most 
lipophilic by-product (fraction 5) had a retention time as long as 45 min. Radio-TLC analysis 
of the corresponding fractions resulted in Rf-values of 0.31 for p-[18F]MPPF (fraction 1) and 
0.64 for the late eluting product (fraction 5). The labelled impurities eluting between them 
showed no retention and were detected with the solvent front. LC-MS data of the analysed 
fractions (1-6) is presented in Fig. 8. The inactive product eluting from semi-preparative 
HPLC at 20 min was identified as the non-labelled precursor p-MPPNO2 with a mass-to-
charge ratio (m/z) of 462 (i.e. protonated molecule, [M+H]+). The mass of the isolated product 
fraction (retention time = 14 min) corresponded the molecular mass of the p-[18F]MPPF, m/z 
435 ([M+H]+). However, 18F-fluorinated by-products were measured with various mass 
peaks, mainly at m/z ratios higher than 400. 
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Fig. 8. Crude p-[18F]MPPF analysed by HPLC with UV (lower chromatogram) and 
radioactivity detection (upper chromatogram). Corresponding fractions were collected from 
the semi-preparative HPLC (marked with numbers 1-6) and analysed with LC-MS. The m/z 
ratios of the major peaks are marked on the measured fractions. 
 
In order to get more information on the possible origin of the various mass peaks, the inactive 
precursor p-MPPNO2 was analysed separately and the results are shown in Fig. 9. Using a 
direct infusion technique m/z of 462 ([M+H]+) was measured, as expected. The spectra also 
showed a peak at  m/z 270, that is, with loss of m/z 192. The molecular mass peak with m/z 
462 was isolated and fractionated in MS2 –mode and a similar major fractionated peak was 
found at m/z of  270.  In  MS3 it has also a fractionated peak at m/z 150, lower by 120 m/z. 
Similar fractionation was detected for the inactive product reference p-MPPF, where peaks 
were detected at m/z 435 and 243 (and 123 in MS3).  
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Fig. 9. ESI-MS analysis of p-MPPNO2 and p-MPPF measured by direct infusion technique. 
Mass peaks and main fraction peaks are marked on the spectra. Drawn line delineate 
corresponding degradation site on the molecular structure.  
 
Stability of the starting material p-MPPNO2 (and the product reference p-MPPF) was also 
studied in cold reaction conditions (DMSO, 180 ?C, 5 min, in the presence of dry K 2.2.2 / 
K+). However, side-products with similar or higher lipophilicity than p-MPPNO2 were not 
detected by the radio-HPLC analysis. Furthermore, HPLC separation of the cold reaction 
mixture containing the product reference resulted in one major peak corresponding to p-
MPPF; other peaks possibly originating from the reference compound were not detected.  
 
5.3. Synthesis of ?11C??-CFT-FP and ?18F??-CFT-FP (III-IV, unpublished data) 
The radiochemical incorporation of [11C?methyl triflate to yield ?11C??-CFT-FP was 40-50% 
(by radio-HPLC); reaction with ?-CFT-FP proceeded instantaneously and no heating was 
required. Furthermore, the optimal molar ratio between ?-CFT-FP-acid and the base was 1:1. 
Purification by the reversed-phase HPLC system resulted in high radiochemical purity. The 
total synthesis time for purified ?11C??-CFT-FP was 25-30 min resulting in 30-40% overall 
radiochemical yield (calculated from ?11C?carbon dioxide, decay-corrected). 
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Production of the 18F-labelled form, [18F]?-CFT-FP, by direct 18F-fluorination of Tos-?-CFT-
FP resulted in ? 1% (decay-corrected to end of bombardment, EOB; n=4) overall 
radiochemical yield of [18F]?-CFT-FP with approximately 80 min synthesis time. Only 
4.6±2.8% (mean±SD, n=2) radiochemical incorporation yield was achieved in the 18F-
fluorination reaction, in addition, a large amount of 18F-radioactivity remained in the semi-
preparative HPLC column. During the labelling studies the amount of Tos-?-CFT-FP was 
increased from 3 mg to 9 mg, however, the labelling yield was not improved. Eventually, no 
18F-fluorination reaction was accomplished. Analysis of the starting material revealed that 
Tos-?-CFT-FP was decomposing within time: toluene sulfonyl was detached from the 
fluoropropyl moiety.  
In the first two-step approach, [18F?fluoropropyl bromide was produced efficiently 
(approximately 90% incorporation from [18F]F- in radio-HPLC) by labelling of 1,3-
dibromopropane. Subsequent 18F-fluoroalkylation of nor-?-CFT (2-4 mg) with 
[18F?fluoropropyl bromide resulted in a 25% (by radio-HPLC) radiochemical incorporation 
yield of ?18F??-CFT-FP after 10 min reaction time. The labelling yield was improved (to 37%) 
in the presence of base, furthermore, the highest ICYs (maximum 85% with K2CO3) were 
achieved when the reaction time was prolonged to 30 min. The total synthesis time was 120 
min, leading to 2.2±1.1% overall radiochemical yield of purified ?18F??-CFT-FP (decay 
corrected to EOB, mean±SD, n=3).  
Synthesis of the second 18F-fluoroalkylation agent, [18F]fluoropropyl tosylate, was studied 
under various conditions: the best radiochemical yield was 61±4% (mean±SD, n=6) using 10 
mg of 1,3-propanediol-di-p-tosylate and a 10 min heating time at 90 ?C (incorporation from 
[18F]F- by radio-HPLC 80%). Extending the reaction time did not have a significant effect on 
the yield. [18F]fluoropropyl tosylate was purified by trapping it into a C-18 cartridge and 
subsequently eluting with DMF. By this SPE method the labelling reagent was separated quite 
efficiently from the unreacted [18F]F-, but the starting material 1,3-propanediol-di-p-tosylate 
eluted in the same fraction. Using a straight-phase cartridge SiO2 some  [18F]F- followed 
[18F]fluoropropyl tosylate but the separation from it and especially from 1,3-propanediol-di-p-
tosylate was improved by changing the eluent from pure ether to a hexane:ether mixture. 
Nevertheless, this method required evaporation of the solvent, which prolonged the synthesis 
time and increased radioactivity losses. Thus, as none of the SPE methods proved to be 
optimal for purification of [18F]fluoropropyl tosylate, this step was excluded from the 
synthesis procedure.  
18F-Fluoroalkylation of nor-?-CFT  with  [18F]fluoropropyl tosylate resulted in highest 90% 
radiochemical incorporation yield when 7.5 mg of nor-?-CFT and 25 min reaction time at 135 
?C was used. The lower reaction temperature (90 ?C)  failed  to  produce  [18F]?-CFT-FP. 
Raising the reaction temperature (150 ?C) or prolonging reaction time over 25 min did not 
improve the yield. In addition, the effect of base on the labelling reaction with 
[18F]fluoropropyl tosylate could not be demonstrated. [18F]?-CFT-FP was purified by HPLC. 
The overall radiochemical yield of the separated [18F]?-CFT-FP was 18±2% (mean±SD, n=3) 
after a 90 min synthesis time, leading to a greater than 30% decay-corrected yield. The 
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radiochemical purity exceeded 99%. The overall RCY of the formulated [18F]?-CFT-FP at the 
end of synthesis (EOS) was approximately 10%. The specific radioactivity of [18F]?-CFT-FP 
at EOS was 15?30 GBq/?mol. The stability of the product was confirmed for up to 8 hours 
after  EOS,  at  which  time  the  radiochemical  purity  of  [18F]?-CFT-FP remained greater than 
97%. 
 
5.4. Biodistribution of ?18F??-CFT-FP ex vivo in rats (V) 
Uptake of 18F-radioactivity in representative rat organs and peripheral tissues at various time 
points after the i.v. injection of [18F]?-CFT-FP is presented in Table 4. At earlier time points 
(5–30 min) the highest levels of radioactivity were measured in the kidneys, pancreas, 
intestine and liver (as well as in thymus and salivary glands). Radioactivity in these organs 
decreased rapidly after 30 min. The relatively high uptake in the small intestine contents 
remained nearly unchanged over time. Uptake values of the urinary bladder, including urine, 
were high from 15 min onwards.  At later time points accumulation of 18F-radioactivity was 
detected in bone, and at 120 min one of the highest uptake values was measured also for 
subcutaneous fat. 
 
Table 4. Uptake (%ID/g) of 18F-radioactivity in rat organs and tissues at various time points 
after injection of ?18F??-CFT-FP.  
Organ/tissue Time point     
 5 min [n=4] 15 min [n=5] 30 min [n=3] 60 min [n=3] 120 min [n=3] 
Blood 0.34 ? 0.09 0.31 ? 0.05 0.27 ? 0.03 0.155 ? 0.005 0.04 ? 0.03 
Bone (skull)  0.13 ? 0.03 0.27 ? 0.07 0.6 ? 0.1 1.12 ? 0.06 1.4 ? 0.5 
Brain (whole) 1.3 ? 0.4 0.44 ? 0.06 0.24 ? 0.04 0.11 ? 0.01 0.08 ? 0.02 
  Cerebellum 0.8 ? 0.3 0.30 ? 0.05 0.18 ? 0.03 0.097 ? 0.008 0.06 ? 0.01 
  Cortex 1.6 ? 0.6 0.6 ? 0.2 0.23 ? 0.03 0.12 ? 0.01 0.07? 0.02 
  Striatum 2.5 ? 0.7 0.8 ? 0.2 0.38 ? 0.09 0.18 ? 0.03 0.10 ? 0.03 
Fat, subcutaneous 0.12 ? 0.07 0.20 ? 0.02 0.3 ? 0.2 0.29 ? 0.03 0.23 ? 0.05 
Feces 0.013a 0.011a 0.05 ? 0.01b 0.12a 0.05 ? 0.02b 
Small intestine wall 1.3 ? 0.3 0.7 ? 0.2 0.8 ? 0.2 0.44? 0.04 0.28 ? 0.05 
Small intestine contents 0.6 ? 0.2 0.37 ? 0.07 0.52 ? 0.09 0.6 ? 0.1 0.6 ? 0.2 
Large intestine wall 0.5 ? 0.2 0.3 ? 0.1 0.4 ? 0.1 0.24 ? 0.02 0.17 ? 0.03 
Large intestine contents 0.16 ? 0.03 0.13 ? 0.02 0.13 ? 0.06 0.19 ? 0.01 0.20 ? 0.07 
Liver 1.1 ? 0.3 0.7 ? 0.2 0.52 ? 0.07 0.247 ? 0.009 0.15 ? 0.06 
Kidneys 1.8 ? 0.3 1.4 ? 0.4 1.0 ? 0.3 0.49 ? 0.08 0.3 ? 0.2 
Pancreas 1.5 ? 0.3 0.6 ? 0.1 0.42 ? 0.09 0.20 ? 0.02 0.14 ? 0.06 
Salivary glands 0.9 ? 0.1 0.9 ? 0.2 0.9 ? 0.2 0.4 ? 0.2 0.3 ? 0.2 
Spleen 0.5 ? 0.1 0.44 ? 0.06 0.33 ? 0.06 0.175 ? 0.005 0.11 ? 0.05 
Thymus 1.1 ? 0.3 0.7 ? 0.2 0.43 ? 0.09 0.17 ? 0.04 0.08 ? 0.03 
Urinary bladder and urine 0.5 ? 0.4 2.8 ? 1.5 2.3 ? 1.4 6.0 ? 2.5 3.6 ? 0.8 
Total urine 3.2 ? 4.4 7.0 ? 2.4 8.2 ? 5.9 13.7 ? 2.5 24 ? 15 
Values are expressed as mean±S.D. 
a n=1. 
b n=2.  
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Accumulation of 18F-radioactivity in brain was measured from the whole brain, as well as 
from tissue samples of striatum, frontal cortex, and cerebellum. Radioactivity accumulated 
rapidly in the striatum: the uptake value at 5 min was 2.49%ID/g. Cerebellar uptake at the 
same time point was 0.81%ID/g. The decay-corrected uptake values were used to calculate 
region-to-cerebellum uptake ratios (mean ? SD) in striatum and frontal cortex, time courses 
of these ratios are depicted in Fig. 10. The striatum-to-cerebellum ratio reached the maximum 
value of 3.13?0.59 within 5 minutes, whilst for the frontal cortex-to-cerebellum ratio, the 
highest value was 1.98?0.13 at 5 min. 
 
 
 
Fig. 10. Time courses of striatum-to-cerebellum and frontal cortex-to-cerebellum 
radioactivity uptake ratios after injection of [18F]?-CFT-FP. Values are expressed as 
mean±S.D. 
 
Pre-treatment with GBR12909 significantly reduced the uptake of 18F-radioactivity in the 
striatum. Autoradiograms of representative brain sections from an untreated control rat and a 
GBR12909 pre-treated rat are shown in Fig. 11. 
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Fig. 11. Autoradiograms of representative ex vivo rat  brain  sections  at  15  min  after  [18F]?-
CFT-FP injection. The upper row depicts a control rat, and the lower row depicts a rat 
pretreated with the DAT inhibitor GBR12909. The autoradiograms show the regional 
distribution of the 18F radioactivity (red indicates the highest levels; blue, the lowest levels), 
with nonspecific uptake partly subtracted. STR indicates striatum; AMY, amygdala; HIP, 
hippocampus; LC, locus coeruleus; RAP, raphe nuclei; SN, substantia nigra; CTX, frontal 
cortex; and CERE, cerebellum. 
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6. DISCUSSION 
 
6.1. Different approaches in 18F-chemistry  
Success of the nucleophilic 18F-fluorination is highly dependent on the reactivities of the 
[18F]F- ion as well as the leaving group. Recently, it was suggested that both of these may be 
enhanced using protic solvents. In this work, the effect of protic solvents, in particular the 
influence of the leaving group on reaction yields in protic solvents in comparison to 
conventional aprotic solvents, was studied by the labelling of 4-(R1-methyl)benzyl R2-
benzoates: benzylic position is typically a good labelling position due to its high reactivity, 
activation by the ester group enables 18F-fluorination also on the aromatic position. 
18F-Fluorination on the benzylic position proved to be successful both in aprotic and protic 
solvents though the best radiochemical yields were achieved in all reaction conditions using 
CH3CN. Mechanistic studies have indicated that the effective hydrogen bonding between the 
oxygen atoms of the mesylate group and OH-groups of the solvent have a role in enhancing 
SN2 reaction rates in t-BuOH (Oh et al. 2007, Kim et al. 2008). This advantageous feature 
was also seen in this study: radiochemical yields in protic solvents were comparable to RCY 
in CH3CN with only the sulfonate ester compound 3, at 120-160 °C. Tert-alcohols were not 
able to promote 18F-fluorination of the benzyl halides 1-2 to the same extent, though the 
higher reaction temperature resulted in higher RCY. The reason for this can only be 
speculated, it could be for example pressure build-up inside the reaction vial, as both t-BuOH 
and t-amyl alcohol have a boiling point lower than 110°C.  
Recently, it was suggested that the efficiency of protic solvents in nucleophilic fluorination 
comes from not only the synergistic effect of a large counterion (Cs) and a protic solvent; but 
also due to the presence of the CsF ion pair that contributes to the reaction (Oh et al. 2007, Im 
et al. 2009, Park and Lee 2010). With the conventional K 2.2.2/[18F]KF phase transfer system 
such catalytic effect may be prohibited by the presence of cryptand. Thus, for comparison the 
compound 2a was labelled in tert-alcohols  using  [18F]CsF, with and without K 2.2.2. The 
results showed that cryptand is needed in tracer conditions for solubilising the [18F]alkali 
metal fluoride and for subsequent 18F-fluorinations (Table 3). Furthermore, higher 18F-
fluorination yields were achieved with K 2.2.2/[18F]KF when compared to K 2.2.2/[18F]CsF.  
Reduction  of  unwanted  side  reactions  is  one  of  the  common  advantages  of  protic  solvents  
(Kim et al. 2008), however, this was not achieved with benzylic starting materials in this 
study. Labelling of compounds 1-3 resulted in a higher amount of labelled side-products in 
protic solvents when compared to aprotic solvents, the difference was more pronounced in 
the highest reaction temperatures and with halide leaving groups. It is well known that in 
basic conditions, especially with alkyl halides, elimination may be favoured over SN2 
substitution (March 1992). However, in this study the competing elimination would have lead 
to non-labelled side products, and thus only decrease the radiochemical yield. Therefore, it is 
probable that the labelled side products were arising from the degradation of the 18F-
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fluorinated product. Their more polar nature suggests the formation of 
([18F]fluoromethyl)benzyl alcohol, for example,  as a result of ester hydrolysis.  
SNAr reactions are known to be much more demanding on the nucleophilicity of the attacking 
nucleophile when compared to SN2 reactions (March 1992). In this study, the compound 4 
was not 18F-fluorinated suggesting that the reactivity of [18F]F- was not enhanced to overcome 
the poor leaving group ability of the aromatic iodide. Successful 18F-fluorination of the 
compound 5 in aprotic solvents confirmed that activation by the ester group was sufficient for 
the substitution reaction with [18F]F- when a known good leaving group, NO2, was applied. 
However, tert-alcohols were not able to facilitate this SNAr reaction even when the solvent 
with higher boiling point, t-amyl alcohol (b.p. 102 °C), was used. 18F-Fluorination of the 
compound 5 was studied in t-BuOH system using also [18F]CsF, with and without K 2.2.2, 
and no aromatic 18F-labelled product was achieved for either conditions. Thus, it may be that 
nucleophilicity of fluoride is weaker in protic solvents. Furthermore, utilisation of tert-
alcohols in aromatic 18F-fluorinations would require a highly reactive leaving group such as 
reported recently in the literature (Olberg et al. 2010).  
In many cases, the use of microwaves has shown to be beneficial for aromatic 18F-
fluorinations (Stone-Elander and Elander 2002), affording the desired 18F-labelled products, 
such as 18F-fluorinated benzamides, with good radiochemical yields in a short reaction time 
(Le Bars et al. 1998, Vandecapelle et al. 2004). In this work, heating with microwaves was 
compared with the conventional thermal heating in the radiolabelling of p-[18F]MPPF. p-
[18F]MPPF was produced with moderate radiochemical yield and 2-4 radioactive by-products 
were formed; furthermore, the best radiochemical yield was achieved with conventional 
heating (180 ?C, 5 min). The use of microwaves enabled a minor decrease in the reaction 
time, but it did not improve the RCY of p-[18F]MPPF nor prevent the formation of the 
radioactive by-products. In addition, without temperature (and pressure) control the 
microwave system was more difficult to handle when compared to thermal heating. 
 
6.2. Comparison of labelling strategies for ?-CFT-FP  
[11C?Methyl triflate is a widely used reagent for 11C-labelling reactions (Lundkvist et al. 
1998, Någren et al. 1995, Dollé et al. 2006a) and afforded also in this work fast incorporation 
of  [11C?methyl group into the 2?-carboxy position of the tropane ring. ?11C??-CFT-FP was 
produced with high RCY (30-40%) and radiochemical purity, using a low amount (0.5 mg) of 
inactive starting material, ?-CFT-FP acid. The overall synthesis time was less than 2 half-
lives of 11C, thus acceptable for 11C-tracers. Specific radioactivity was not determined; 
however, using a similar labelling procedure another phenyl tropane derivative, [11C]PE2I, 
was produced with a SA of 55 GBq/ µmol (Halldin et al. 2003).  
Labelling of ?18F??-CFT-FP was achieved by N-18F-fluoroalkylation of corresponding 
desmethylated starting material, nor-?-CFT. ?18F??-CFT-FP was produced reproducibly with 
high radiochemical and chemical purity, as well as with reasonable specific radioactivity, 
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15?30 GBq/?mol, using ?18F?fluoropropyl tosylate as the labelling agent. The overall 
synthesis time was 105 min leading to 10% RCY at EOS, which should allow production of 
?18F??-CFT-FP in clinical amounts for PET studies. Moreover, the optimised synthesis 
procedure was simpler and faster, resulting in higher radiochemical yield for the purified 
product (decay-corrected yield over 30%) when compared to labelling with ?18F?fluoropropyl 
bromide. 18F-Fluoroalkylation with ?18F?fluoropropyl bromide required a protracted and 
complicated purification step for the labelling reagent, which led to a long synthesis time 
(120 min) and poor overall radiochemical yield, 2.2±1.1% (decay-corrected) for the purified 
?18F??-CFT-FP, respectively.  
Stochiometric conditions proved to be important when the intermediate purification of the 
[18F]fluoropropyl tosylate was omitted from the synthesis procedure. The unreacted 1,3-
propanediol-di-p-tosylate competes with the labelling reagent in the alkylation of nor-?-CFT, 
thus equimolar amounts of inactive starting materials were needed to achieve the highest 
incorporation of [18F]fluoropropyl tosylate into ?18F??-CFT-FP. In contrast to labelling with 
[18F]fluoropropyl bromide, addition of base did not improve the 18F-fluoropropylation yield. 
Tosylate itself is a better leaving group than bromide (Block et al. 1986), moreover, without 
intermediate purification the reaction mixture contains base (CO32-)  from  the  [18F]F- 
activation.  
Direct 18F-fluorination of toluene sulfonyl ester proved to be an unsuccessful method for the 
production of ?18F??-CFT-FP due to the instability of the starting material: the tosylate group 
was eliminated from Tos-?-CFT-FP and the remaining salt could not be 18F-fluorinated. 
Degradation was most probably arising from the basic conditions that were used in the 
separation of Tos-?-CFT-FP from its sulfonic anhydride starting material. Direct 18F-
fluorinations have typically been less successful labelling methods for phenyl tropane 
analogues as the highly reactive sulfonate esters suffer from instability and competing side 
reactions  (as  well  as  epimerization  to  an  unwanted  isomer),  leading  to  poor  RCY  of  the  
desired product (Wilson et al. 1995, Chaly et al. 1999). Nevertheless, a simple, one-step 18F-
fluorination would be advantageous considering purification and automated production of 
?18F??-CFT-FP. Recently, the iodine analogue ?18F??-CIT-FP was produced both from N-
fluoropropyl mesylate and tosylate esters with improved radiochemical yields using TBAOH/ 
[18F]F- system and t-BuOH as a solvent (Lee S.J. et al. 2007b, 2011). As tert-alcohols were 
shown to be effective solvents in the labelling of sulfonate ester also in this work (Paper I), it 
would be interesting to investigate whether 18F-fluorination in tert-alcohols would be feasible 
also for the production of ?18F??-CFT-FP.  
 
6.3. Radioanalytical methods  
18F-Fluorinated products were evaluated by the conventional chromatographic techniques, 
TLC and HPLC. Combined to high sensitivity radioactivity detection techniques they were 
both feasible methods for the radiochemical analysis of the labelled products, that is, 
determination of radiochemical incorporation yield and radiochemical purity of the final 
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products. However, radiosynthesis of p-[18F]MPPF resulted in numerous 18F-fluorinated by-
products. Radiochromatographic analyses showed that these radioactive impurities were less 
polar than the desired compound p-[18F]MPPF, but other conclusions on the nature/origin of 
these compounds could not be drawn without a number of non-radioactive reference 
materials. Therefore, MS was used as an additional method for the qualitative analysis of the 
labelled products.  
The radiochemical yield of p-[18F]MPPF in the test syntheses was low but nevertheless 
sufficient to show that the mass of the isolated product fraction corresponded the molecular 
mass of the p-[18F]MPPF in the LC-MS analysis. The most significant 18F-fluorinated by-
products (fractions 4 and 5) were detected at m/z ratios higher than 400 (Fig. 8). Furthermore, 
in most cases, analysis of one fraction resulted in various peaks, some of them at very high 
m/z ratios, thus it is probable that the non-radioactive impurities, and adduct ions formed from 
them, were interfering with the measurements. The measured m/z ratios were compared to the 
data obtained from the (ESI)-MS analysis of the inactive reference compounds. Analysis of p-
MPPNO2 and p-MPPF showed the original mass peaks, m/z 462 for p-MPPNO2 and 435 for 
p-MPPF ([M+H]+), and peaks at m/z ratios smaller than 192, suggesting vulnerability of basic 
nitrogen on the piperazinyl moiety (Fig. 9). Further fractionation (MS3) resulted in peaks at 
m/z ratios smaller than 120 which are likely arising from the cleavage of the amide bond as 
presented in Fig. 12. In the LC-MS analysis of the 18F-fluorinated fractions corresponding 
peaks were not detected. Thus, it was concluded that the labelled side-products resulted from 
degradation of p-[18F]MPPF through a route other than C-N cleavage or amide hydrolysis. An 
alternative explanation may come from the decomposition of p-MPPNO2 and subsequent 
labelling of the fragments, though the exact mechanism could not be resolved. Altogether, it 
was shown that the sensitivity of ion trap MS is sufficient for the qualitative analysis of 18F-
labelled compounds and it is a valuable tool in further radiosynthesis development work.  
 
 
Fig. 12. Molecular structure of p-[18F]MPPF  (R  =  18F) and p-MPPNO2 (R  =  NO2). Drawn 
lines delineate considered degradation sites. Masses of the resulting fragments are calculated 
for decomposition of the labelled product.  
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6.4. Radiolabelled ?-CFT-FP as a tracer for DAT  
A number of radiolabelled cocaine analogues have been developed and evaluated for their 
pharmacokinetic properties to find a suitable radiotracer for quantitation of DAT in the 
human brain in vivo by PET. In this work, the phenyl tropane analogue [18F]?-CFT-FP was 
evaluated by determining its biodistribution ex vivo in rats.  
18F-Radioactivity accumulated rapidly into the brain; the highest uptake occurred in the 
striatal area which contains the greatest amount of DAT. The maximum uptake value, 
2.49?0.72%ID/g, was already reached within 5 minutes, after which it cleared rapidly. This 
indicates both good BBB penetration as well as reversible binding kinetics for the tracer. The 
rapid washout, thus poor retention of [18F]?-CFT-FP, is also in agreement with its relatively 
low affinity (47.9 nM) for DAT (Harada et al. 2004). Similar fast, reversible type kinetic 
behaviour in rats has been reported for the 18F-fluoropropylated chlorine analogue, N-(3-
[18F]fluoropropyl)-2?-carbomethoxy-3?-(4-chlorophenyl)nortropane ([18F]FPCT) (Goodman 
et al. 1997). Reversible binding kinetics in vivo is preferred for brain PET studies. Although 
given that rodents, like the rats in this study, usually show faster kinetics of radioligands than 
primates, [18F]?-CFT-FP should reach equilibrium in primates within a reasonable PET 
scanning time. Moreover, monkey PET studies on the structural fluoroethyl analogue [18F]?-
CFT-FE showed that equilibrium was reached in the striatum, with a striatum-to-cerebellum 
uptake ratio of 4, about 20 min post injection (Harada et al. 2004). The maximum striatum-to-
cerebellum uptake ratio for [18F]?-CFT-FP was 3.13?0.59, thus relatively low when 
compared to its parent compound [18F]?-CFT for example (approximately 10 at 120 min 
post-injection, p.i.) (Haaparanta et al. 1996, Marjamäki et al. 2010), but it may still be 
sufficient for PET studies on human striatal DAT sites that are expressed with high density. 
Pre-treatment with the selective DAT inhibitor, GBR12909, significantly decreased 18F-
radioactivity uptake in the rat striatum; significant [18F]?-CFT-FP binding was not observed 
in the raphe nuclei or in the hypothalamus where serotonin transporters (SERT) are abundant 
(D’Amato et al. 1987, Sur et al. 1996), nor in regions where noradrenaline transporters (NET) 
are located, such as the locus coeruleus (Burchett and Bannon 1997). The striatum has a high 
density of DAT but contains only intermediate levels of SERT, and NET is virtually absent 
(Lorang et al. 1994, Hoffman et al. 1998). Thus, these results are in agreement with earlier 
studies suggesting that ?-CFT-FP is a selective ligand for DAT with much lower affinity for 
SERT and NET (Kämäräinen et al. 2000, Harada et al. 2004). 
In peripheral tissues, the kidneys, pancreas, small intestine wall, and liver showed the highest 
levels of 18F-radioactivity at the earlier time points, which were decreased thereafter. This 
indicates specific binding to DAT: in addition to its presynaptic location, DAT is present at 
several extraneuronal locations, such as the stomach, pancreas and kidneys (Torres et al. 
2003, Eisenhofer 2001). Furthermore, the non-neuronal catecholamine transporters (organic 
cation transporters: OCT1 and OCT2) that are responsible for limiting the spread of the signal 
and for clearance of catecholamines from the bloodstream, show a broad tissue distribution, 
including the liver, intestine, kidneys (Eisenhofer 2001). The high uptake values in the 
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urinary bladder after 15 min and the relatively high constant uptake in the small intestine 
contents indicate that [18F]?-CFT-FP and/or its metabolites were eliminated by urinal and 
fecal excretion.  
Increasing accumulation of 18F-radioactivity in bone as a function of time indicates in vivo 
defluorination of [18F]?-CFT-FP. Similar behaviour was reported for the chlorine analogue 
[18F]FPCT: accumulation in the bone was initially low, 0.27%ID/g at 5 min, but increased to 
1.58%ID/g at 120 min, suggesting moderate stability of the 3-fluoropropyl group in vivo in 
rat (Goodman et al. 1997). In subcutaneous fat, 18F-radioactivity uptake peaked at 60 min and 
remained at a relatively high level until 120 min, which reflects accumulation of lipophilic 
radioactive metabolites. Previous studies on the structural analogues of [18F]?-CFT-FP have 
shown that the N-18F-fluoroalkylated compounds undergo fast metabolism (Lundkvist et al. 
1997, Goodman et al. 1997, 2000, Davis et al. 2003). Furthermore, some of the resulting 
polar radiometabolites have shown to be able to penetrate the BBB and spread uniformly in 
the rat brain (Zoghbi et al. 2006). [18F]?-CFT-FP can be anticipated to have similar metabolic 
behaviour and the increased radioactivity background level should thus be considered in the 
quantitation of DAT. Compared to the N-18F-fluoroalkylated compounds, the methyl ester 
labelling position for 11C-cocaine analogues may offer higher in vivo stability and slower 
metabolism, but a competing radiometabolite [11C]nor-?-CFT is formed (Gatley et al. 1994, 
Lundkvist et al. 1995, 1997). Nevertheless, taking into account the fast kinetics of ?-CFT-FP 
[11C]?-CFT-FP might also be a useful tracer for DAT. 
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7. CONCLUSIONS  
 
? A series of 4-(R1-methyl)benzyl R2-benzoates were labelled with nucleophilic 18F for a 
detailed study of the effect of protic solvent on SN2 and SNAr reactions. Both the desired 
benzylic and aromatic 18F-fluorinated products were achieved with the highest yield 
using the K 2.2.2/[18F]KF phase transfer system and conventional aprotic solvents, 
CH3CN and DMF. However, tert-alcohols  proved  to  be  effective  co-solvents  in  the  
labelling of the sulfonate ester and may thus be considered as useful solvents for similar 
types of 18F-fluorination reactions.  
 
? The radiochemical analysis of the labelled products was carried out by conventional 
radiochromatographic methods. However, both the radio-TLC and –HPLC methods 
without a broad reference material were inadequate in the assessment of the various 
radioactive by-products of p-[18F]MPPF. Characterisation by the LC-(ESI)-MS method 
showed that sensitivity of the ion trap MS is sufficient for the qualitative analysis of 18F-
labelled products.  
 
? The radiolabelled ?-CFT-FP could be produced from corresponding precursors both as a 
11C- and 18F-labelled form. [18F]?-CFT-FP was produced most efficiently by the two-step 
procedure using [18F]fluoropropyl tosylate as the 18F-fluoroalkylating agent. The 
optimised overall radiosynthesis method enables production of [18F]?-CFT-FP with good 
radiochemical yield, high chemical and radiochemical purity, as well as with reasonable 
specific radioactivity.  
 
? The biodistribution studies in rats showed promising properties, including specific and 
selective binding of [18F]?-CFT-FP to the dopamine transporter sites in addition to fast 
kinetics. Thus, it was concluded that [18F]?-CFT-FP  has  potential  as  a  radiotracer  for  
imaging human striatal DAT function.  
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